- PANDEMIC RESPONSE
- CORPORATE STATE
-
INFORMATICS
-
HEALTH AUTHORITIES
- NIH (National Institute of Health)
- NIST (National Institute of Standards and Technology)
- CDC (US Center for Disease Control)
- UKHSA (UK Health Security Agency)
- EIC (European Innovation Council)
- Bill and Melinda Gates Foundation (US Healthcare Charity)
- WELLCOME TRUST (UK Foundation)
- NIAID (National Institute of Allergy and Infectious Diseases)
- BARDA (Biomedical Advanced Research and Development Authority)
-
GLOBAL CORONAVIRUS CLINICAL TRIALS
- WHO: Therapeutics and Covid-19: Living Guideline
- GAVI: Global Vaccine Alliance
- CDC: Latest Vaccine Price List
- Doctors Laboratory: Coronavirus Covid-19 PCR/Antibody Testing
- BCDCC Canada: Covid-19 Vaccine Safety
- Oxford Com-Cov: Oxford Vaccine Group’s Com-Cov Combination Tracking
- Covid-19: Vaccine Tracker (Candidates, Trials, Approvals)
- GOVERNMENT AGENCIES
- HETERODOX TRACKERS
- ORTHODOX TRACKERS
- NATIONAL GUIDELINES
-
HEALTH AUTHORITIES
- R & D
- NARRATIVES
- TIMELINE
PANDEMIC RESPONSE
SARS-CoV-2 TESTING
Do you know the difference between SARS-CoV-2 and Covid-19? Over 90% of adults do not.
- SARS-CoV-2 is the coronavirus and it is susceptible to antivirals and prevention measures (prophylactics)
- Covid-19 is the immunological consequence of contracting the coronavirus and it may require treatment
- Covid-19 severity is measured by hypoxia and biochemical and immunological indicators (CRP, D-Dimer etc)
Since early 2020, the public has been asking: “Why is there no transparency about Covid? Why no open data?”
Why isn’t comprehensive data being collected/made available, despite the calls of medical experts?
There is a criminal failure at the heart of public health management – and it can’t be 100% accidental
Why has there been so little emphasis and such a lack of progress on testing and testing infrastructure from early 2020 to today?
Vaccines help but aren’t 100%. Danger comes from someone infected not someone unvaccinated. What about antigen testing preboarding?
Why won’t anti-vaccine sentiment go away? Why is it intensifying and spreading?
TESTING CONCERNS
- Anything less than best possible testing to minimise virus spread 100% risks public health
- Lack of honest open data is a big reason millions reject Covid-19 vaccine i.e. they conclude no data equals proof of grift
- Lack of testing networks speak to unprecedented confusion or obfuscation in public health authority pandemic management
- Anything less than full spectrum testing is perpetuating the virus
- Total testing would need to test antibody tiers (IgA, IgM, IgG) and B-cell/T-cell activation (immunological memory)
- PCR + antigen (lateral flow) combination testing show both infectiousness and immune system neutralising antibody titers
- If testing is not free, testing will happen less for poor/working people, perpetuating the virus
- If testing is not standardised, test results will not give consistent data, perpetuating the virus
- Some vaccinated (and some unvaccinated) are super-spreaders but there’s no data whether vaccine or natural immunity leads to less infectiousness
- Without comprehensive testing protocols standardised and part of coordinated public health response Coronavirus will become endemic
TESTING OBSERVATIONS
- Proper testing shows up individual infectiousness and/or immunity (neutralising antibodies) to SARS-CoV2
- Testing is non-discriminatory but if it costs money, it will discriminate against poor/working class
- Antigen (lateral flow) test very accurate for “am I infectious?” but inferior to PCR for immune system antibody response
- PCR test doesn’t target infectiousness – which is dumb and defeats the purpose of gateway portal test point mandates (e.g. airports)
- France and other European countries test for neutralising antibodies (PCR) which is accepted as vaccine equivalent but doesn’t show infectiousness
- USA vaccine restrictions and vaccine mandate satisfied by proof only, no interest in antibodies, no widespread antigen (lateral flow) test protocols
- UK testing and travel guidelines take into account immunity (PCR) but make limited use of antigen (lateral flow) at borders
PUBLIC HEALTH TESTING FAILURE
- Public health independent experts point out transparent open data – simple honesty – is the best way to ensure confidence and overcome vaccine hesitancy
- Why is there no publicly available data on neutralising antibody levels for natural immunity?
- Why is there no public data tracking on vaccine-induced immunity (antibody response)?
- Why is there no public nexus testing (e.g. wastewater) – to reveal outbreaks so public health resources can target efficiently?
- When there’s a lack of public data it means public health policy is subordinated to political and corporate-profit agenda
- There’s no public data tracking ongoing testing of antibody/immunity of people from vaccine trials (completions or terminations)
- There’s no public data tracking cases (infections) unvaccinated, natural immunity, vaccine immunity (2 doses, 3 doses, etc) over time
- Why wasn’t testing focused on neutralising antibody titers from April/May 2020 as the most effective, useful data before treatment or quarantine/lockdown (or, later, vaccination)?
- Why do none of the available SARS-CoV-2 testing protocols include the full spectrum of neutralising antibody IgG IgM IgA + aggressive T-cell titers + memory B-cell activation?
- Daily rapid antigen testing targets minimisation of viral spread, which is what we want eliminated, rather than simply targeting the exclusion of unvaccinated, which won’t necessarily limit viral infections
- Individual neutralising antibody / infectiousness test results can’t be faked – unlike vaccine certificates or vaccine passports
- Individual immune system response to vaccine (or prior infection) varies wildly – it defies logic to fixate on ‘got vaccine’ to prevent spread
- Why is there almost no coherent variant tracking? Why is variant testing left to pooling and extrapolation?
TESTING KIT GRIFT
- Why aren’t antigen (lateral flow) tests available in the home and at every public portal (airport, venue, office, mall, etc)?
- Try finding price of an antigen testing kit – very simple, surely?
- SingClean (on Linkedin) supplies Germany and is authorised by German govt
- If you’re in Germany you can see prices but not if you’re in the UK or the USA where it’s censored
- Try searching Ali Baba simply for Covid-19: all results are censored
- FDA has only authorised Coronavirus test kits as medical devices – effectively creating an impossible barrier to entry
- FDA approval criteria includes a testing infection period that’s designed to serve market exclusion of antigen (lateral flow) test type
- FDA medical devices standards ensure only PCR tests can return high accuracy, antigen tests at best 30% accurate by dint of testing only infectious participants
- This means the only way to get FDA authorisation (EUA) for rapid antigen (lateral flow) tests is to cheat or bribe – hence hardly any antigen tests available in the US and those available sell at 20-50x cost of manufacture
How can it be “Vaccine or Test” when vaccine doesn’t stop infectiousness – and logically it would be “Vaccine AND Test”?
How can a vaccine passport be better than a sufficient up to date negative antigen (lateral flow) test i.e. “not infectious”?
Why do mandates not take a negative Covid-19 test + high antibody score or negative antigen (not infectious) result not equivalent (or better) to vaccination certification?
VACCINE IMMUNITY
- Given the vaccination objective is to get the immune system to work up antibodies against exposure to Sars-COV2, why’s there no combination of testing infectiousness and tracking of post-vaccine/post-infection antibody response?
- Shouldn’t that be the basis for vaccine need?
- Wouldn’t it also create a non-judgmental way to encourage vaccine hesitant to get the shot?
- Antibody/T-cell/B-cell numbers show who has reacted well to vaccination, who may need boosters, who’s fought off SARS-CoV2 and acquired natural immunity, who may need vaccine despite a prior infection
- Covid testing (PCR) measures active circulating antibodies, not immunological memory (i.e. long-term immunity)
- Circulating antibody titers are not predictive of T-cell or B-cell long-term immunological memory
- Most important, the antibody/T-cell/B-cell immune system numbers show how safe a person is from being infected and/or infecting others with Coronavirus
- Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections (25-Aug-2021)
SARS-CoV-2 TEST TYPES
PCR TEST
- The quantitative IgG antibody test selectively detects antibodies directed against the protein S at the spike of the virus. Since all the vaccines currently in use are addressing this specific protein S, the test allows to adequately measure the human immune response resulting from vaccination as well as immune responses resulting from a prior infection. The test can be performed after recovery and any time during the vaccination period but is recommended after 2-3 weeks post vaccination.
- Cellular immunity tests, on the other hand, isolate immune cells and stimulate them with spike proteins of the virus. This enables measurement of the amount and activity of T-Cells, which are responsible for eliminating ill or altered cells. T-Cells together with antibodies make up the human immune response. Therefore, cellular immunity tests are complementary to antibody tests.
- COVID-19 Vaccine Effectiveness Test
ANTIGEN (LATERAL FLOW) TEST
- Antigen test is fast and cheap – less than $1 per test to produce at scale
- Antigen test isn’t as accurate at detecting immunity but is perfect for testing infectiousness which is what matters in public health
PUBLIC TESTING INFRASTRUCTURE
- Rapid T-B-nA testing: antigen = lateral flow
- At home antigen tests for infectiousness
- Rapid public peer-reviewable results
- Judiciously placed testing points (e.g. at schools, malls, public transport interchanges, etc)?
- Free testing as a public health priority
- Free treatment if testing results show infection and high risk
- Proper testing has 100% demonstrable benefits
- Proper testing has no downside except cost to government and shifting the needle away from purely political public health policy
WHO PAYS?
- Polling shows even the vaccine hesitant are not against regular testing if it’s free and especially if it’s a test they can take at home
- In economic terms, testing is surely cheaper than potentially bankrupting disruption of sledgehammer lockdowns – cost benefit analysis makes this clear
- The major difference between focus on testing and fixation on lockdown is who pays: testing is a govt expense, lockdown expense hits the citizen/business
PANDEMIC CLARITY
- How can there be no pandemic test-and-trace – or at least test-and-advise – protocol?
- Coronavirus outbreaks are reduced to zero if the R (infection rate) is below 1 – target doesn’t have to be zero
- Waste water testing should be ubiquitous
- The UK authorised and distributed antigen tests for free to everyone
- How can governments (and institutions) argue endlessly over mask mandates in schools, vaccinating children, lockdowns, freedoms curtailed, quarantines, travel restrictions, when these could be settled by an open, logical, follow-the-data decision making?
- Pool testing is unnecessarily vague yet it’s US standard – almost as if it’s trying to prolong pandemic by deindividuating positive Covid-19 testing
- FDA/CDC public health refuses at home antigen testing because “it might change behaviour” – a pre-Covid standard – but what about pregnancy kits?
- Testing doesn’t need to be welded to tracking if the link creates public discontent
- There’s a wilful repetition of the presumption testing must always include tracking that’s too consistent to be accidental
- Test-and-trace (instead of simply comprehensive T-B-nA testing) distracts public scrutiny away from REAL government failure (or refusal) to fund simple provision of comprehensive testing infrastructure by instead stoking fear of future abuse (tracking surveillance)
ARTICLES
- SARS-CoV-2 Sewage Monitoring Data
- Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening (25-Jun-2020) | (27-Jun-2020) | (8-Sept-2020) | (1-Jan-2021))
- The hidden public health hazard of rapid Covid-19 tests (5-Nov-2020)
- RAPID ANTIGEN TEST VS LATERAL FLOW (13-Oct-2021)
- Rapid $1 Covid-19 tests exist. Why can’t we get them? (27-Aug-2020)
- Using viral load and epidemic dynamics to optimize pooled testing in resource constrained settings (6-Oct-2020)
- Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK (19-Nov-2020)
- The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review (22-Jan-2021)
- Put to the test: use of rapid testing technologies for covid-19 (3-Feb-2021)
- Executive summary: It’s wrong not to test: The case for universal, frequent rapid COVID-19 testing (19-Feb-2021)
- Dr. Michael Mina’s Rapid Test Theory: Calls for At-home, Non-prescription Rapid Tests (29-Mar-2021)
- Coronavirus (COVID-19): Press Conference with Michael Mina, 04/01/21 (1-Apr-2021)
- Testing at scale during the COVID-19 pandemic (4-May-2021)
- Review of Current COVID-19 Diagnostics and Opportunities for Further Development (7-May-2021)
- COVID-19 testing turns to T cells (12-May-2021)
- Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study (30-Jun-2021)
- Coronavirus (COVID-19): Press Conference with Michael Mina, 10/06/21 (6-Oct-2021)
- The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity (21-Oct-2021)
- Verifying immunity – SYNLAB helps people to monitor their immunity status after vaccination against and recovering from SARS-CoV-2 (Mar-2021)
- Doctors Laboratory: Coronavirus Covid-19 PCR/Antibody Testing
- Home Rapid Tests: Singclean Rapid COVID-19 Self Diagnostic | Nasal Self-Testing Kits
- Concierge MD: Covid-19 In Home Testing (America only)
PANDEMIC RESEARCH
- Blockchain and Artificial Intelligence Technology for Novel Coronavirus Disease-19 Self-Testing (1-Apr-2020)
- Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays (14-Jun-2020)
- Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer (23-Jul-2020)
- A Data-Driven Rationale for High-Throughput SARS-CoV-2 Mass Screening Programs (10-Dec-2020)
- Effects of regular testing as a sort of Covid-19 filter, by identifying, isolating and thus filtering out currently infected persons, using antigenic tests among healthcare workers in three hospitals in the South of Italy (29-Jan-2021)
- High-Frequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test (17-Feb-2021)
- COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August-October 2020 (13-Mar-2021)
- Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study (1-Apr-2021)
- Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study (10-Apr-2021)
- The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic (7-May-2021)
- Asymptomatic rapid testing for SARS-CoV-2 (7-Jul-2021)
- COVID-19: a review of current knowledge regarding exposure, quarantine, isolation and other preventive measures (14-Jul-2021)
- Pooled SARS-CoV-2 antigen tests in asymptomatic children and their caregivers: Screening for SARS-CoV-2 in a pediatric emergency department (24-Jul-2021)
- Empirical evidence to understand the human factor for effective rapid testing against SARS-CoV-2 (10-Aug-2021)
- Diagnostic Accuracy of SARS-CoV-2 Antigen Tests for Community Transmission Screening: A Systematic Review and Meta-Analysis (15-Aug-2021)
- Graphene-Based Technologies for Tackling COVID-19 and Future Pandemics (16-Sept-2021)
- Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture (2-Nov-2021)
- Test sensitivity for infection versus infectiousness of SARS-CoV-2 (12-Nov-2021)
- Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients (24-Nov-2021)
- Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial (26-Nov-2021)
- Visualisation: Coronavirus Mechanism of Entry and Transcription
- Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
- Entrectinib – a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells
- Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19
- Sars-Cov-2 antibody titer 3 months post-vaccination is affected by age, gender, smoking and vitamin D
- How Informative were Early SARS-CoV-2 Treatment and Prevention Trials?
- No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
CORONAVIRUS IMMUNITY
BASIC POINTS ON IMMUNITY
- Prior infection and Covid-naive vaccination and vaccination after recovery from Covid-19 can all reduce risk and levels of SARS-CoV-2 infection
- Vaccine immunity – and to a lesser extent natural immunity – protect to varying degrees depending on the continued mutation evolution of variants
- Vaccines and prior infection will accelerate viral clearance even if infected
- Fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and will efficiently transmit infection, including to fully vaccinated contacts
- Host–virus interactions early in infection may shape the entire viral trajectory including amount of SARS-CoV2 viral exposure and individual immune system factors
EXPOSURE – INFECTION – RECOVERY – RESISTANCE
- Exposure: if you are exposed to a lot of SARS-CoV2 it will infect you and could hit you hard (symptoms, Covid-19 severity)
- Infection: including symptoms and Covid-19 severity – will be reduced in severity by vaccine and past immunity (i.e. by neutralising antibodies and immunological memory)
- Recovery: if you’re hit hard by Covid-19, the silver lining is high level of long-lasting antibodies and immunological memory, i.e. potentially long lasting resistance
- Resistance: if you’re exposed to SARS-CoV-2 and it infects you but your natural or vaccine immunity clears the virus quickly, the downside is lower level of priming of immune system against future coronavirus
IMMUNE SYSTEM: 5 ANTIBODY TYPES
- IgA. IgA antibodies are found in areas of the body such the nose, breathing passages, digestive tract, ears, eyes, and vagina. IgA antibodies protect body surfaces that are exposed to outside foreign substances. This type of antibody is also found in saliva, tears, and blood. About 10% to 15% of the antibodies present in the body are IgA antibodies. A small number of people do not make IgA antibodies.
- IgG. IgG antibodies are found in all body fluids. They are the smallest but most common antibody (75% to 80%) of all the antibodies in the body. IgG antibodies are very important in fighting bacterial and viral infections. IgG antibodies are the only type of antibody that can cross the placenta in a pregnant woman to help protect her baby (fetus).
- IgM. IgM antibodies are the largest antibody. They are found in blood and lymph fluid and are the first type of antibody made in response to an infection. They also cause other immune system cells to destroy foreign substances. IgM antibodies are about 5% to 10% of all the antibodies in the body.
- IgE. IgE antibodies are found in the lungs, skin, and mucous membranes. They cause the body to react against foreign substances such as pollen, fungus spores, and animal dander. They are involved in allergic reactions to milk, some medicines, and some poisons. IgE antibody levels are often high in people with allergies.
- IgD. IgD antibodies are found in small amounts in the tissues that line the belly or chest. How they work is not clear.
IMMUNE RESPONSE
- The immune system has numerous distinct and complimentary kinetics of immunological memory:
- IgA prevents viral replication in the upper airways (nose/throat) – where Omicron variant particular targets
- Vaccination is more predictable in strong short-term antibody IgM/IgG response than naive prior infection
- Vaccines and prior infection generate IgM then IgG but only natural infection promotes antibody IgA
- Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections (25-Aug-2021)
VACCINE IMMUNITY
- Vaccines infection generates IgM then IgG antibodies but doesn’t promote antibody IgA or long-term immunological memory
- Vaccine immunity is waning over time (3-6 months plus) and also losing efficacy as variants evolve
- Vaccine immunity focus is on spike protein not other aspects of SARS-CoV-2 hence narrow but strong specific antibody response
- Immunity from vaccination + prior symptomatic infection = high level short-term antibodies IgM IgG and IgA and long-term immunological memory IgA
- Vaccine efficacy and natural immunity vary greatly between individuals and by viral load exposure, severity of past Covid-19, SARS-CoV-2 variant
- mRNA vaccine causes higher short-term immunity response to coronavirus but wanes after 3-6 months
- adenovirus vector vaccines not as high as mRNA short-term but as a more traditional mechanism the protection wanes slower
- Vaccination is effective for 3-6 months after double/boosted dose (in sampled participants):
- Vaccination primes the circulating antibodies IgM and IgG against SARS-CoV-2 spike protein – positive titers from vaccine is well proven
NATURAL IMMUNITY
- Symptomatic infection from Covid-19 creates substantial natural immune memory across all kinetics
- Natural immunity is giving cross immunity to successive variants so far from alpha to Omicron
- About 95% of subjects retained immune memory at ~6 months after infection i.e. natural immunity
- Natural infection provides immunity to SARS-CoV2 – extent of antibody response depends on severity of infection
- Natural immunity lasts longer but short-term may not be as strong as vaccine immunity
- Natural (prior infection) immunity can be combined with vaccination
- Documented cases of unvaccinated with prior Covid-19 infection (natural immunity):
- Estimated efficacy 94·8%
- Hospitalisation prevention 94·1%
- Severe illness 96·4%
- MoH Summer Surge Data:
- Between 5 July and 3 August over half a million infected but unvaccinated
- 1% of weekly new cases were in people who had previously had Covid-19 (natural immunity)
- Antibodies against SARS-CoV2 spike and receptor binding domain (RBD) declined moderately over 8 months
- Memory B cells against SARS-CoV2 spike increased between 1 week and 8 weeks after infection
- Proportion of subjects positive for CD4+ T cells (92%) remained high at 6 to 8 months after infection
ARTICLES / STUDIES
- Original Antigenic Sin
- What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? (11-Dec-2020)
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (5-Feb-2021)
- Natural infection versus vaccination: Differences in COVID antibody responses emerge (24-Aug-2021)
- Stakeholder Call – Myocarditis and Pericarditis Updates (29-Jun-2021)
- Proof of natural immunity shown by a positive PCR test result for COVID-19, lasting for 180 days after the date of the positive test
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel (20-Apr-2021)
- Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 (14-Oct-2021)
- ECPDC: Immune Responses and Immunity to SARS-CoV2
- The molecular basis for public T-cell responses? (Mar-2008)
- Chicken Pox Vaccine overview
- Site-specific analysis of the SARS-CoV-2 glycan shield (28-Mar-2020)
- Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein (9-Apr-2020)
- Spike Mutations – Potential Implications for Vaccine T Cell Responses
- Computational epitope map of SARS-CoV-2 spike protein (1-Apr-2021)
- Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (29-Apr-2021)
- Had COVID? You’ll probably make antibodies for a lifetime (26-May-2021)
- SARS-CoV-2 variants: levels of neutralisation required for protective immunity (13-Aug-2021)
- What Happens to the Immune System after Vaccination or Recovery from COVID-19? (20-Sept-2021)
- Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response (13-Sept-2021)
- High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines (24-Sept-2021)
- Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain (25-Sept-2021)
- The pandemic in Europe, 2020.01.20 – 2021.11.20 (20-Nov-2021)
PUBLIC HEALTH COMMENTS
- Dvir Aran, Technion: “These numbers look very low. The data suggest that the recovered have better protection than people who were vaccinated.”
- Peter Marks, FDA: “We know that the immunity after vaccination is better than the immunity after natural infection.”
STUDY DATA
- Natural infection data (USA Feb 2020 to May 2021):
- 0 – 17 26.8 / 73 37%
- 18 – 49 60.5 / 138 44%
- 50 – 64 20.4 / 62 32%
- 65+ 12.3 / 54 23%
- Total 120.3/ 328 37%
- N = 254 blood samples post infection
- N = 51 long term follow up
- Antibodies against SARS-CoV2 spike and receptor binding domain (RBD) declined moderately over 8 months
- Memory B cells against SARS-CoV2 spike increased between 1 week and 8 weeks after infection
- Proportion of subjects positive for CD4+ T cells (92%) remained high at 6 to 8 months after infection
We found that Spike antibodies showed better durability than Nucleocapsid antibodies. During the first six months, spike antibodies also showed better durability (half-life 97 days) than the subset of Spike-RBD antibodies (half-life 62 days), whereas both Nucleocapsid and N-RBD antibodies showed similar persistence (half-life 47 days). Similar conclusions were drawn in a study by Fenwick et al. [42] who reported differential waning of SARS-CoV-2 humoral responses, with antibodies recognizing the trimeric Spike being more persistent compared to antibodies recognizing nucleocapsid. The analysis of our cohort revealed a bi-phasic decline of antibodies with an inflection point at ~6 months post symptom onset.
MASKS AND VENTILATION
PUBLIC POLITICS
- 18+ months into pandemic, how can there be no definitive public health protocols for mask use?
- Why is there so little thorough study data on masking, mask policy or airflow viral load?
- Why has the study of masking been allowed to be a merely political / civic law enforcement wedge issue?
- Public health should be organised as a medical issue regardless of which “team” is in power
- There should surely be no uncertainty about these basic issues of public health
- The next pandemic may be worse
MASK AND FILTRATION FACTS
- Cloth, silk and other fabric masks are not effective
- Studies show unequivocally: any mask below N95 rating is not useful against SARS-CoV-2
- Air filtration systems are exponentially more effective than masking using current widely available technology
- Planes have filtration systems running the air with over 99% effectiveness at removing airborne (aerosol) particulates
- HEPA air filtration (as on planes) is the equivalent of permanently worn N99+ mask
MASK POLICIES
- USA: California, New York City, Florida, Colorado, Seattle, Oregon
- UK: England, Scotland, Wales, Northern Ireland, Gibraltar
- EU: Germany, France, Austria, Spain, Portugal, Italy, Poland, Hungary, Holland
- Global South: Brazil, Argentina, Chile, Australia, New Zealand, South Africa
- Asia: India, China, Taiwan, Japan, South Korea, Israel, Russia, Pakistan, Singapore, Malaysia, Indonescia
COVID-19 PROTECTION IN PUBLIC/HIGH-RISK SPACES
- Studies show cloth masks are not effective – anything below N95 is ineffectual
- PPE for COVID-19 must include, at minimum, N95 respirators or higher, isolation gowns, i.e. standard surgical clothing
- Surgical and non-respirator face masks do not protect persons from aerosolised or airborne infectious diseases and cannot be relied upon for novel pathogens such as COVID-19 over air filtration and – if high-risk exposure – N95+ face masking
- Examples of N99+ mask include: powered Air-Purifying Respirator (PAPR) with high efficiency particulate air filters as protection against aerosol generating procedures on suspected or confirmed COVID-19 cases like ventilated patients
- Open and continuous communication about any potential exposure to suspected or confirmed COVID-19 cases
- Screening protocols to identify patients who may have COVID-19 infections
- Plans to ensure prompt isolation of patients with suspected or confirmed COVID-19 infections in airborne infection isolation rooms
- Protective PPE for nurses and other health care workers providing care to patients with suspected or confirmed COVID-19 infections including airborne and contact precautions
- PPE for COVID-19 must include, at minimum, N95 respirators or higher, isolation gowns, eye protection, and gloves
- OSHA recommends that if N95 respirators are not available, employers should use higher levels of respiratory protection such as N/P/R100s, elastomeric respirators, powered-air purifying respirators, and others
- A Powered Air-Purifying Respirator (PAPR) with high efficiency particulate air filters must be worn during aerosol generating procedures on suspected or confirmed COVID-19 cases
- All donning and doffing should be performed in a separate room, with a buddy system to ensure efficacy and hands on training
- 14 days paid precautionary leave for a nurse or other health care worker who is exposed to COVID-19 – ended with two negative antigen tests (1-2 days apart)
- Exposure incident procedures: Employers must identify, evaluate, and investigate potential worker exposures including techniques like wastewater testing – locally managed medical and testing follow-up services must be provided, free of charge, to all exposed employees
VENTILATION INFO
- All Your Coronavirus Questions, Answered [including Masking] (14-Apr-2020)
- COVID-19 (Corona Virus) and Air Filtration Frequently Asked Questions (FAQs)
- Which air purification technologies can tackle COVID-19? (12-Mar-2021)
- ScienceDirect: How can airborne transmission of COVID-19 indoors be minimised? (22-Apr-2020)
ARTICLES / STUDIES
- Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers (March-2021)
- Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine (29-Oct-2020)
- Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers (2020)
- Buzzfeed: Here’s What You Need To Know About Air Purifiers And Coronavirus (3-Mar-2020)
- Aura Air filter tackles COVID-19 virus in vehicles (2-Jul-2020)
- Pandemic Proofing Travel (3-Jul-2020)
- Researchers Create Air Filter That Can Kill The Coronavirus (7-Jul-2020)
- Newly designed air filter can ‘catch and kill’ COVID-19 (10-Jul-2020)
- SCIENTISTS DESIGN “CATCH AND KILL” AIR FILTER THAT KILLS 99.9 PERCENT OF THE CORONAVIRUS CAUSING BACTERIA IN PUBLIC SPACES (13-Jul-2020)
- The Atlantic: We Need To Talk About Ventilation (30-Jul-2020)
- COVID-19 destroying air filter tested in opticians enters the market (10-Nov-2020)
- Indoor Ventilation Strategies to Reduce the Spread of COVID-19 at Home (5-Apr-2021)
- We should install air purifiers with HEPA filters in every classroom. It could help with COVID, bushfire smoke and asthma (18-Aug-2021)
- COVID-19 has spurred investments in air filtration for K-12 schools – but these technologies aren’t an instant fix (24-Aug-2021)
- How Can You “Follow The Science” When There Is “No Science Behind Mask Mandates For Children”? (31-Aug-2021)
- Real-world data show that filters clean COVID-causing virus from air (6-Oct-2021)
- Sen. Johnson for The Federalist: The Worst Is Yet To Come From Biden’s Vaccine Coercion (14-Oct-2021)
- ‘Virus-killing’ air filtration system unveiled by Cambridge scientists and engineers’ (25-Oct-2021)
- Air filter significantly reduces presence of airborne SARS-CoV-2 in COVID-19 wards (16-Nov-2021)
- Protections at Work for Covid-19 (Apr-2020)
- DANMASK-19 Mask Study Analysis:
- NIH: Mask Mandates After DANMASK-19 (Jan-2021)
- No Significant Effect for Facemask Wearers (19-Nov-2020)
- A Review of the Evidence: Studies of Mask Efficacy – Do Masks Work? (22-Aug-2021)
TREATMENT AND PROPHYLAXIS
Why is there zero definitive info on medical prophylaxis?
Why no policy on individual prevention?
Why no open debate on evolving treatment protocols?
OBSERVATIONS
- Much talk about cases of damage from the spike protein post-vaccine but reasons have been hard to pinpoint. Could it be down to not asperating the needle prior to injection, and thus occasional inadvertent injection of the vaccine into the bloodstream – which is known to be extremely dangerous?
- How many who’ve had the vaccine got their needles aspirated?
- Why would there be aggressive, partisan exclusion of ANY prophylactic that’s cheap and universal and proven safety record?
- Amplifying overdose victims is propagandist; never sincere.
CONSIDERATIONS
- Vaccine gives (high estimate) 90% protection from SARS-Cov2
- Ivermectin prophylactic + treatment inclusion adds 0%-5% protection (i.e. it is useless or it is a bit useful)
- End result potentially saves tens of thousands of lives WITH the antiviral versus withou
- No downside to using all possible probable non-harmful preventions,m treatments, etc
- Where’s the medical logic in banning ivermectin or predisposing against any medication promising even a single percentage better outcome likelihood?
- Regeneron makes REGEN-COV: a mixture of two monoclonal antibodies: casirivimab and imdevimab
- “[Regeneron] is an important treatment before you get to the hospital” Dr Nancy Foster, President Travis County Medical Society
- “It must be given before symptoms worsen to the point of a patient being hospitalized. If you show up to the ER short of breath, it’s too late” Dr Scott Clitheroe, Travis County Medical
PREVENTATIVE and EARLY TREATMENT
- Is the dosage level required to get enough ivermectin into play for anti-Sars-CoV2 viral replication significant? Because Pfizer’s last line of defense for its ritonivir combo drug (that works like ivermectin) is it needs a much lower (safer) dosage to be effective as an anti-SARS-CoV2 protease inhibitor
- Where’s the medical logic in banning ivermectin or predisposing against any medication promising even a single percentage better outcome likelihood?
- Could this be because while Ivermectin inhibits many mechanisms (as you’ve reported), this makes it less effective – by dose – against any one specific mechanism? Might this require higher dose Ivermectin to be as effective as Pfizer’s Paxlovid, which targets only one mechanism?
- (Even though obviously the Pfizer drug is far more likely to become resisted by viral mutation as it is single mechanism rather than Ivermectin’s multiple mechanisms of action)
- Is the dosage per mechanism significant? I’ve not yet found a paper answering this question!
INTERVENTIONS
- VITAMIN D
- TOCILIZUMAB
- Severe COVID-19 can develop cytokine release syndrome (“cytokine storm”) with high IL-6 concentrations
- Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R)
- Demonstrated effective against the cytokine storm
- BUDESONIDE
- OTHER MEDS – OTHER VIRUS
- Zinc for the common cold (18-Jun-2013)
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab (27-Oct-2021)
- Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds—Practical Advice on Dosages and on the Time to Take These Nutrients/Botanicals in order to Prevent or Treat Common Colds (29-Apr-2018)
- Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome (20-May-2018)
- BIOTECH
TREATMENT PROTOCOLS
- FLCCC Protocols: A Guide to Management of COVID-19
- I-MASK+ Prevention and Early Outpatient Treatment for COVID-19
- MATH+ Hospital Treatment Protocols for COVID-19
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (28-Nov-2021)
- Dr Peter McCullough Early Treatment Protocol (2-Dec-2021)
- COVID-19 Rapid Guideline: Managing Covid-19 (UK NICE)
- Therapeutic Management of Nonhospitalized Adults With COVID-19 (USA NIH)
- Therapeutic Management of Hospitalized Adults With COVID-19 (USA NIH)
- A Guide to Home-Based COVID Treatment (28-Aug-2021)
TREATMENT ARTICLES
- Are both supplemental magnesium and vitamin K2 combined important for vitamin D levels? (10-Mar-2020)
- Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review (14-Jul-2020)
- Initial data shows arthritis drug is effective in treating sickest Covid-19 patients (19-Nov-2020)
- Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (21-Nov-2020
- Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 (25-Jan-2021)
- COVID-19 nasal spray effective against variants (2-Jul-2021)
- Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) (20-Jul-2021)
- Queen Mary researchers help develop nasal spray that prevents Covid-19 (27-Sept-2021)
- UK biotech and University of Birmingham in licensing deal for nasal spray targeting COVID-19 (9-Nov-2021)
- Developing a nasal spray to prevent COVID-19 infection (22-Nov-2021)
- 15 Best Drug Combination Treatment Studies for COVID-19 (5-Dec-2021)
VACCINES AND MANDATES
VACCINE TYPES
VACCINE PROS AND CONS
- Reduces likelihood of hospitalisation (and worse) for elderly, comorbidities and immunocompromised – which is the majority of the population
- Vaccine efficacy against Covid-19 – especially hospitalisation and life-threatening complications – remains demonstrable even for young people, unless specifically at risk
- Antibody levels in part come from extent of viral load exposed
- Passing natural infection might engender lower antibodies than a double or triple (i.e. regular) dose of vaccine
- Natural immunity is absorbed into long-term B-cell memory as mRNA inspired response does not
- Systemic side-effects from vaccine especially mRNA vaccine more common in people previously infected
- Science by Press Release is never honest
- Vaccine immunity is demonstrated neutralising antibodies IgM/IgG but less convincing on IgA and long-term immunological memory B-cell stimulation
- Vaccines tend to give more definitive high equivalent viral load so can stimulate less variable IgM/IgG antibody and some T-cell response than – for example – low viral load natural exposure
VACCINE SIDE EFFECTS
- Large UK study of systemic/vaccine side effects after natural infection:
- 1·6 times after the first dose of ChAdOx1 nCoV-19
- 2·9 times after the first dose of BNT162b2
- 56% more likely to experience a severe side effect that required hospital care
ADVERSE REACTIONS
- REACT19/CovidLongHauler: Vaccine Injury Reporting & Treatment
- YOUTUBE: US Senate – Expert Panel on Federal Vaccine Mandates and Vaccine Injuries
- Myocarditis Pericarditis – mRNA vaccine POTS: Kyle Warner (pro-mountain biker)
- Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning (28-Jun-2021)
- Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture (25-Jun-2021)
- Covid Long Haulers: Dr Bruce Patterson | Dr Yogendra | Incelldx.com
- Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection (26-Jul-2021)
- ImmuniTrack: immunogenicity assessments
- CENSORSHIP OF OPEN DISCUSSION:
VACCINES FOR YOUNG AND OLD
- Vaccination seems to reduce likelihood of hospitalisation (and worse) for elderly, comorbidities and immunocompromised but needs boosters every 6-12 months
- Vaccines probably reduce likelihood of severe illness including hospitalisation and death for young and middle-aged versus naive natural infection – 3-6 months after most recent vaccination
- Young have greater absolute risk from vaccination versus older people though risk is very low (under 1%) across all agees
- Older people and immunocomprimised people much higher risk from Coronavirus
- Severe illness including hospitalisation and death exponentially higher impact by comorbidities (including being fat, low Vitamin D) than vaccine status
- Young people recover fast
- Young males risk greater from mRNA vaccination than from Covid-19
- Should young people be forced to take the individual risk for the sake of older, vulnerable members of the public?
- Myocarditis young – especially young males – incident percentages higher than simply catching Covid and higher than baseline – possibly lack of aspiration?
- Incidents of myocarditis and pericarditis in Norway (no aspiration) 240% higher than Denmark (aspiration) same vaccine, same 90%+ vaccinated population
- Vaccine efficacy press release 2020: overall efficacy 92·8% | prevent hospitalisation 94.2% | prevent severe illness 94.4% | prevent death 93.7%
VACCINE MANDATES
- CDC recommends: full vaccination dose(s) for everyone including children, mandated boosters for all elderly, mandated for immunocompromised, mandated for frontline health workers and other public workers, recommends booster for all J&J single dose vaccinated, recommends boosters for all vaccinated after 6 months
- CDC data: US CDC All-Causes Mortality (2013-2022)
- Federal Reister: Fourth Amendment to the Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19 and Republication of the Declaration (9-Dec-2020)
- OSHA.GOV: Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace (29-Jan-2021)
- Substack: The FDA’s ‘Bait and Switch’ with Pfizer’s COVID Vaccine (27-Aug-2021)
- David Gorska: Yes, the FDA really HAS given full approval to the Pfizer/BioNTech COVID-19 vaccine (30-Aug-2021)
- Fox News: Sen. Ron Johnson: There is not an FDA approved COVID vaccine in the US (1-Oct-2021)
- Federal Register: COVID-19 Vaccination and Testing; Emergency Temporary Standard (5-Nov-2021)
- Appeals Court: Petition to US Appeals Court Sixth Circuit (30-Nov-2021)
- US Supreme Court: Emergency Application For An Administrative Stay And Stay of Administrative Action, And Alternative Petition For Writ Of Certiorari Before Judgment (17-Dec-2021)
- District Court: US Navy Seals v President Biden: Court Judgment (3-Jan-2022)
- Dr Robert Malone: Serve, Suffer and Sacrifice (4-Jan-2022)
- CDC: COVID-19 Vaccinations in the United States, Jurisdiction (4-Jan-2022)
- Aaron Siri: Reply Filed in the U.S. Supreme Court to the Government’s Claim of Nearly Unlimited Authority to Force Private Companies to be the Vaccine Police (4-Jan-2022)
- Court Filing: Informed Consent Action Network – Covid Vaccine Mandates (28-Dec-2021)
PATENT SHARING
Pfizer/Moderna (i.e. NIH – as patent holder) aren’t sharing their vaccine recipe because they need to protect the mRNA platform, quite separately from the debate over proliferating vaccination against SARS-CoV-2 in the context of saving lives in the Coronavirus pandemic.
It’s possible the big pharmaceutical corporations don’t object to letting poor countries make their own vaccines. The problem is with sharing the mRNA platform itself – specifically – because it is a multipurpose technology way beyond targeting spike proteins with potential for revenue streams that dwarf the billions made from SARS-CoV-2.
The mRNA platform has myriad uses as a cancer delivery drug, which is perhaps the biggest prize in medical science – a bonanza of incalculable trillions that could roll on and on for decades. This is why the patent isn’t going to be shared. It won’t be shared until the technology can be shared in a way that doesn’t open access beyond targeted Coronavirus usage. The vaccine corporations will doubtless be working on a nerfed version. If they find it, there will be a fanfare of “patent sharing”.
VACCINE DEVELOPMENT PAPERS
- Natural infection versus vaccination: Differences in COVID antibody responses emerge (24-Aug-2021)
- The Race to Understand Post–COVID-19 Conditions (31-Aug-2021)
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity (13-Jul-2012)
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike Immunogen: induces potent humoral and cellular immune responses (28-Sept-2020)
- Adenoviral vectors are the new COVID-19 vaccine front-runners: Can they overcome their checkered past? (12-May-2020)
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogens (30-Oct-2017)
- Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment (18-Sept-2020)
- Winton Centre Summary (Cambridge) – Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine (7-Apr-2021)
- BMJ: Review of COVID-19 vaccine subtypes, efficacy and geographical distributions (8-May-2021)
- Finnish-developed, open-source coronavirus vaccine nearly ready for testing (8-May-2020)
- Finnish researchers introduce nasal spray Covid “vaccine” (8-Mar-2021)
- Future of Finland’s Covid nasal spray vaccine uncertain (7-May-2021)
- Ivermectin nasal spray supposedly on patent by Finnish startup Therapeutica Borealis is UNPROVEN (25-Aug-2021)
PHARMACOLOGIES
- APOBEC3A apolipoprotein B mRNA editing enzyme catalytic subunit 3A [ Homo sapiens (human) ]
- APOBEC3G: an intracellular centurion (12-Mar-2009)
- Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase (5-May-2009)
- APOBEC3 proteins mediate the clearance of foreign DNA from human cells (17-Feb-2010)
- Frequently Asked Questions on the EUA of REGEN-COV (Regeneron: Casirivimab and Imdevimab) (19-Oct-2021)
Bioscience Tech
AD-VECTOR Tech (AstraZeneca)
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (30-Apr-2021)
- To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia (5-Aug-2021)
- From 4 January to 4 August AstraZeneca vaccine in the UK: 24.8M + 23.9M doses with 412 suspected CVST (Cerebral Sinus Vein Thrombosis) 89% first dose (14.9 per million), 11% second dose (1.8 per million). CVST as a complication of COVID-19 infection 42.8 per million. Of the 411 cases 73 were fatal
- Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death (24-Jun-2019)
- ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome (1-Dec-2021)
- Covid: Trigger of rare blood clots with AstraZeneca jab found by scientists (2-Dec-2021)
mRNA Tech (Pfizer, Moderna)
- CellScript LLC – RNA for Translation in Cells (2011)
- Cellscript INC – Registered Patents (2010-2013)
- NIH – Moderna – Confidential Contract – License Agreements Contracts (6-Nov-2015 to 27-Aug-2020 )
- OSIVAX: Newly Founded French Biotech is All About Vaccines (23-Jun-2016)
- mRNA Technology Licensing Agreement between CellScript LLC of Madison, WI and ModernaTx Inc (26-June-2017)
- BioNTech Enters Into Licensing Agreement With CellScript LLC – Messenger RNA (6-Sept-2017)
- License Agreement: BioNTech RNA Pharmaceuticals GmbH (“BioNTech”) and Genevant Sciences GmbH (4-Jul-2018)
- Collaboration and License Agreement: Pfizer Inc and BionTech RNA Pharmaceuticals (20-Jul-2018)
- Moderna: Cellscript Securities Exchange Commission Filings (9-Nov-2018)
- Moderna: Science and Fundamentals of mRNA Technology (6-Feb-2019)
- Moderna: Securities and Exchange Commission – Fiscal Year 2019 (28-Feb-2020)
- OSIVAX (France) Proprietory OligoDOM®: OVX313 Technology Platform mRNA lineage technology (1-Sept-2020)
- Pfizer Vaccine’s Funding Came From Berlin, Not Washington (9-Nov-2020)
- Analysis: Pfizer Vaccine Relies on U.S. Government-Developed Spike Protein Technology (10-Nov-2020)
- Advance Purchase Agreement between Pfizer and the European Union (17-Apr-2021)
- Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients (10-Aug-2021)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (13-Aug-2021)
- Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary (22-Aug-2021)
- Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response (13-Sept-2021)
- The Tangled History of mRNA Vaccines (14-Sept-2021)
- Taibbi: The Cult of the Vaccine (8-Oct-2021)
- Moderna Gets Its COVID-19 Miracle (29-Oct-2021)
- Data Integrity Issues in Pfizer’s COVID-19 Vaccine Trial (2-Nov-2021)
ARTICLES
- Injection 101: Overview, Types, Common Uses & Risks
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (7-Jul-2021)
- Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim: Results and Analysis (Jun-2021)
- Fact check: Sen. Ron Johnson (again) misleads on vaccines and reported deaths (29-Jun-2021)
- Twitter Feed: @tlowdon – Covid Infections by Vaccine Status (1-Oct-2021)
- Sen. Johnson for The Federalist: The Worst Is Yet To Come From Biden’s Vaccine Coercion (14-Oct-2021)
- Twitter Feed: @RameshGulla4 – Vaccine Efficacy Duration (17-Oct-2021)
- Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups (Nov-2021)
- Sen. Johnson hosts panel highlighting people claiming to be harmed by COVID-19 vaccines (3-Nov-2021)
- Vaccine-Injured Speak Out, Feel Abandoned by Government Who Told Them COVID Shot Was Safe (3-Nov-2021)
- Covid-19: What next for the Valneva vaccine? (23-Nov-2021)
- EMA starts rolling review of Valneva’s COVID-19 vaccine (VLA2001) (2-Dec-2021)
- Latest Data on COVID-19 Vaccinations by Race/Ethnicity (15-Dec-2021)
- Nigeria destroys more than one million expired COVID-19 vaccines (23-Dec-2021)
PUBLIC HEALTH RESPONSE
PANDEMIC RESOLUTION
DATA PUBLISHING
- Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures (19-Mar-2020)
- Infections is the number/trend generating most of the headlines in the media and on the news:
- It is partly indicative of a rise or fall in SARS-CoV-2 prevalence
- But frequently number of infections fluctuates according to how many tests are being sampled
- Health authorities keen to justify lockdown or more vaccine take up will ramp up testing to generate higher infections so it looks like a sudden spike
- Conversely health authorities trying to look effective and on top of Coronavirus will reduce testing so it suddenly looks like the virus is on the way out
NO COMPLETE PICTURE IS EVER PROVIDED TO THE PUBLIC OR THE HEALTH AUTHORITY
- New infectious are front page news, hospitalizations and deaths are regularly cited in prominent graphics but the circle is never squared by recording (and reporting) recovery alongside infected
- An infection (case) is a key data point but it needs a virus cleared (recovered) data point too
- But at population scale, new positive tests (infections/cases) need follow-up negative tests (recovered, virus cleared) to make useful public policy
- Length of time between infection and recovered
- Provides public # of active infections – i.e. virus prevalence – across a given population, county, outbreak area, etc
- Opens potential for analysis of natural v vaccine immunity in speed of viral clearance, severity of disruption
- Builds coherent non-pharmaceutical corporate trial data on antibody titer levels and impact of virus duration on subsequent immunological response
- Gives public health authorities a direct line on assessing new variant behaviour (e.g. highly infective, mild symptoms, quick to clear or low infection rates but aggressive once it takes hold)
- Hospitalisations listed under Covid-19 are 75% hospitalized for other reasons antigen/PCR testing positive for SARS-CoV-2 after admission
- Variability in death-by-Covid records because half the records list as “death by Coronavirus” anyone who tests positive when kicking the bucket
- Whereas half health authorities only record as a “death by Coronavirus” if the death is caused by Covid-19 directly
COVID PUBLIC HEALTH DATA
- Estimating Influenza-Associated Deaths in the United States (12-Dec-2008)
- Racial and ethnic inequities in the early distribution of U.S. COVID-19 testing sites and mortality (27-Aug-2021)
- Infection fatality rate of COVID-19 inferred from seroprevalence data (1-Jan-2021)
- Racial disparities in knowledge, attitudes and practices related to COVID-19 in the USA (18-Aug-2020)
- Exponential-growth prediction bias and compliance with safety measures related to COVID-19 (16-Sept-2020)
- Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19 (1-Dec-2020)
- Authors Response to Letters to the editor regarding: ‘Assessing mandatory stay- At- Home and business closure effects on the spread of COVID- 19’
- Study claiming new coronavirus can be transmitted by people without symptoms was flawed (3-Feb-2020)
- Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany (5-Mar-2020)
- Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19 (5-Jan-2021)
- COVID-19 antibody seroprevalence in Santa Clara County, California (22-Feb-2021)
- Global perspective of COVID-19 epidemiology for a full-cycle pandemic (7-Oct-2020)
- Huge Number of Hospital Workers Still Unvaccinated (21-Jun-2021)
- Ultra-Vaxxed Israel Now Has Highest CV Case Rate In The World; Sweden Bans Travelers From Israel
- UK Hospitalisations:
- 9,472 people were admitted to English hospitals with the highly transmissible Delta variant of coronavirus between 1 February 2021 and 29 August 2021
- 5,098 people were under 50 | 3,742 (or 73%) of under 50s were unvaccinated | Over 70% of over 50s were vaccinated
- UK Covid Deaths:
- 21-Apr-2021: 127,544 total deaths | 11M double vax (6M double vax + fortnight since second dose)
- 21-Oct-2021: 139,324 total deaths (45M double vax)
- = 11,780 deaths last 6 months – this is double the average annual flu deaths
- Hospitalizations | NHS Capacity:
- 38K hospitalized high point in Jan 2021
- 8k hospitalized current Covid burden on 21-Oct-2021
- UK testing @ 1 million a day via all pillars (testing routes)
- O.N.S Coronavirus (COVID-19) latest insights: 90%+ in UK Antibodies + Vaccinated (16-Sept-2021)
- Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021 (1-Dec-2021)
- “Exemplar study, both useful data, reasonable conclusions and also propaganda by what’s left unstudied and unsaid. Like a hundred other similar studies, it concludes efficacy of vaccine boost plus natural immunity results in better longer lasting immunity than double vaccination alone and natural immunity alone… But this conclusion is burying the question of interrogating the real value of the vaccine immune response in direct comparison to naturally acquired immunity. It is important to highlight this comparison because government enforced mandates are ignoring natural immunity in favour of vaccine passports, forcing those with prior infection to be vaccinated or else submit to expensive testing (if this option is even available). The policy makes no sense as a public health (pandemic minimisation) measure but, if the goal is selling more vaccine, public health is subordinated to profit. Examining these studies in more detail reveals the vaccination is short-lived (3-6 months) and less effective than natural immunity, though an argument could be made for vaccination plus natural immunity as the highest level of protection from current variants of SARS-CoV-2. In light of this, government policies like “Vaccine Or Test” risk prolonging the pandemic – because vaccine efficacy wanes, testing by PCR reveals past/current Covid-19 infection after 2-3 days but not the more important infectiousness (viral shedding) phase like the antigen test picks up in 15 minutes. The only explanations for these policies persisting after over a year into vaccine proliferation are incompetence or profiteering. Neither breed confidence in the vaccine hesitant. Misdirected mandates and lockdown of unvaccinated are therefore criminal abuse of government power.
- Expert reaction to the latest fortnightly release on the COVID-19 Infection Survey looking at antibody and vaccination data for the UK (4-Aug-2021)
- COVID-19 Nursing Home Study (13-Sept-2021)
- Indirect effects of peaks in COVID admissions on access to surgery in the English NHS, differential effects by operation type, ethnicity and socio-economic status: a database study (9-Sept-2021)
“The Great Barrington Declaration” is signed and published in Great Barrington MA (USA) (Kulldorff, Gupta, Bhattacharya 4-Oct-2020) – “As infectious disease epidemiologists and public health scientists we have grave concerns about the damaging physical and mental health impacts of the prevailing COVID-19 policies, and recommend an approach we call Focused Protection”
How do we beat the Coronavirus pandemic?
- Minimise Covid-19 casualties
- Temporary social disruption
- Support against economic damage (especially to small business)
- Protect psychological damage to parents and children
- Reduce SARS-CoV-2 direct and corollary impact on healthspan?
VACCINE
- All vaccine programmes must include properly tracked – with an opt out – no mandates
- ASPIRATION
- Why is there no official protocol for aspirating before injection of vaccine, to ensure none of the vaccine is intravenous?
- Aspirating ensures vaccination goes intramuscular, not intravenous because intravenous is dangerous
- Intravenous doesn’t happen often but it is more common in younger people and warned against by vaccine makers
- Lack of aspiration is the prime candidate for what could be causing the relatively rare but nonetheless real adverse reactions
- Significant incidents of post-vaccine myocarditis, thrombosis and other extreme adverse reactions to the mRNA vaccines in particular
- Because pharmaceutical is immune from prosecution, government is caught in its own trap: it can’t change advice to include aspiration because doing so would admit an astronomical class action by thousands of vaccine injured
- End result of the government covering itself is no change to aspiration advice which directly leads to unnecessary death and suffering (and fuel for vaccine hesitancy)
- MEDICAL ADVERSITY
- Guilt and negligence aside, government must adequately fund full adverse injury cover – especially if big pharmaceutical companies continue to be protected from all liability
- Lack of government sponsored cover for Covid-19 and vaccine adverse effects (injury) is one of the main reasons millions choose to stay unvaccinated
- Contrary to the public messaging vilifying wilful ideological rejection of vaccine, over 75% of unvaccinated are working and precarity classes – disproportionately ethnic minorities, often without a doctor or medical cover
TESTING
- Proper testing (with opt-out on tracking) and fast response to positive tests: antigen in every home
DOCTOR – PATIENT PROPHYLAXIS
- Unshackled doctor-prescribed prophylactics and other treatments per doctor patient relationship
- Particular care for immunocompromised people in particular with a full range of prophylactics
MASKS AND VENTILATION
- Encourage mask use on public transport and indoor spaces but optional; antigen testing at every threshold
- HEPA filtration systems on all enclosed public transport and underground stations/terminus
DATA SCIENCE
- Open data – no censorship – no patrician ‘lies for the perceived public good’
- Full tracking of public antibodies and immunity using PCR testing – especially post-vaccine post-infection
- Vigilant public health measures like wastewater testing, resources targeted on outbreaks
STATE AUTHORITY – MANDATES
- The Significance of the Nuremberg Code
- No mask mandates – no vaccine mandates
- No lockdown – no forced community quarantine
- No closure of business – no curfew – no state-sponsored violence against the citizen
- No travel restrictions but antigen testing at every travel portal
- Public portal antigen protocol: shops, offices, venues, airports, stations, schools, churches, etc
- No vaccine passports – no coercive threat-to-income compelled behaviour
PUBLIC HEALTH MESSAGING
- Public health messaging on co-morbidities including obesity
- Advisories on specific ways to strengthen immune system
- AUSTRALIA DEC 2021: Scott Morrison flags changes to Australia’s COVID-19 approach after National Cabinet meeting (22-Dec-2021)
- Video: Fauci Admits Mandates Are ‘Just a Mechanism’ To Get More People Vaccinated (28-Dec-2021)
BAD FAITH
- Monopoly on science on my side only – ignorant heresy to dispute my orthodoxies
- Ad hominem attack to discredit heterodox opinion is dishonest and counter-productive; and evades taking on the real substance
- Money matters – everybody knows this – so obfuscating profit motives undermines faith
- Health and medicine science is not political – everybody knows this – so every time messaging conflates asserting fact with obvious politicisation it will alienate
ECONOMIC GOOD GOVERNANCE
- Direct and simple financial support for positive test/infected if forced out of work or subject to medication costs
- Government paid sick leave for isolation, forced quarantine, mandate rules, workplace safety, lockdowns, business closures, etc
- Full healthcare coverage (financial, access to care) for Covid-19 medical expenses including vaccine and vaccine injury
- Provision to the public (free of charge) of antigen and PCR testing
- If masking is part of the public response, PPE N95/N99 masks should be provided without charge to everyone advised to mask up
- Sick pay and sickness benefit schemes in the European Union (17-Oct-2016)
- Coronavirus: Employment rights and sick pay – United Kingdom (17-Mar-2020)
- H.R.1319 – American Rescue Plan Act of 2021 (11-Mar-2021)
- AMERICAN RESCUE PLAN ACT OF 2021 – HARDCOPY
- What Employers Need to Know About the American Rescue Plan Act (11-Mar-2021 to 11-Sept-2021)
- Statutory sick pay explained in the UK (up to date Dec-2021)
- Denmark reinstates Covid-19 sick leave compensation for parents and companies (23-Nov-2021)
- IRS: Amounts Paid for Certain Personal Protective Equipment Treated as Medical Expenses (Jul-2021)
PUBLIC HEALTH OBJECTIVES
- Minimise SARS-CoV-2 incursion, spread and longevity in the population
- Encourage robust immunity to SARS-CoV2 across the population
- Encourage focus on reducing comorbidities
- TACKLING COMORBIDITIES
- Why no public health messaging on tackling known comorbidities like weakened immune system or obesity etc?
- Why is there no broadcast messaging about immune system healthiness, like Vitamin D, Zinc, obesity, smoking, judicious diet, fitness, or proven cheap Covid-19 prophylactic nasal spray/eye drops?
- It makes no medical sense whatsoever not to frontline these easy personal interventions likely to save tens of thousands of lives (at the very lowest)
- Vitamin D and the Immune System (Aug-2011)
- Vitamin D Prevent Acute Respiratory Tract Infections: Systematic Review (15-Feb-2017)
- Individual health and individual immune system aids: vitamin D, Zinc, weight loss, less smoking, cardiovascular exercise, etc
- CDC: Obesity, Race/Ethnicity, and COVID-19
PROTECTION AGAINST COVID-19
- Advise all reasonable metrics known to increase protection against Covid-19:
- Test portals
- Air filtration interiors
- Free antibody-appropriate vaccination
- Doctor access to unrestricted antivirals
- Concordant reduction efforts against co-morbidities
- Public advisories on strengthening immune system, citizen trust: antigen tests in every household + isolate when positive antigen with no isolation if/when double negative antigen, community wastewater testing
NATURAL v VACCINE IMMUNITY
- Immunity and immunological memory following smallpox vaccination (2-Nov-2006)
- METRICS
- Antibodies (IgG, IgM, IgT, IgA) against SARS-CoV2
- Stimulate memory B-cells
- Educate killer T-cells
- Reduced SARS-CoV2 viral load
- Shorten period of SARS-CoV2 infectiousness
- Faster viral clearance
- Long-lasting multiple vector antibody titers against future exposure
- OBSERVATIONS
- Unvaccinated with no natural immunity look most likely to be hospitalised by severe Covid-19
- Covid-19 deaths appear to be higher percentage among unvaccinated without natural immunity
- Therefore natural immunity and vaccine immunity reduce severity of Covid-19
- Some evidence supports vaccination giving 3-9 months less likely to be hospitalised, less likely to die
- Contracting Covid-19 is more dangerous than aspirated vaccination as a way to prime immune response
TO VACCINATE OR NOT TO VACCINATE?
- Vaccination gives non-trival boost to antibody immunity against SARS-CoV-2 variants without the risk of contracting the virus
- Natural immunity from infection is broader, more potent and more long-lasting than immunity from vaccine
- Natural immunity depends on the viral load of infecting exposure
- Risks to most people – especially elderly, immunocompromised and co-morbidities – from Covid-19 outweigh natural immunity from naive exposure
- Recovering from the virus gives 8x-12x level of short-term and long-term antibody immunity
- SARS equivalent immunity has lasted 10+ years
- mRNA vaccine immunity is shown to wane considerably after 6 months
- Is it OK to put young lives at greater risk for the sake of older lives potentially facing greater risk, e.g. coronavirus caught by grandkids passed on to grandparents?
- CDC data shows very very low risk from Coronavirus vaccines (mRNA or ad-vector) though the chance of serious side effects increases – separate to co-morbidities – for much younger patients, especially males under 21
- CDC site numbers give between 5000-1 and 20000-1 serious myocarditis/pericarditis risk for mRNA (Pfizer/Moderna) vaccines, especially after second dose
- This risk is far higher than the risk of serious Covid-19, for that age/gender group
- Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: 100 Youths Hospitalized after mRNA Vaccination (13-Dec-2020 to 7-Aug-2021)
CIVIC CONTRAINDICATIONS
- PUBLIC HEALTH SERVICES
- “JCVI says there is insufficient evidence to support giving jabs to all 12- to 15-year-olds”
- “Ministers could defy JCVI and go ahead with Covid jabs for all 12- to 15-year-olds – official vaccine advisers consider margin of benefit too small to support vaccination of entire age group”
- UK government vaccines watchdog rules out Covid jabs for children (3-Sept-2021)
- Vaccinating people who have had Covid-19: why doesn’t natural immunity count in the US? (13-Sept-2021)
- HOSPITAL BURDEN
- CDC November 2020 Covid-19 Burden (11-Dec-2020)
- CDC.gov Covid-19 Healthcare Burden (27-Jul-2021)
- Impact on spread + mental health + harm to social lives + business
- Absolute restriction on freedom versus particular restriction on infected
- INFLUENZA
- How CDC Estimates the Burden of Seasonal Influenza in the U.S.
- Seasonal Incidence of Symptomatic Influenza in the United States (15-May-2018)
- INFLUENZA NUMBERS (from CDC and NHS 2011-2018)
- Symptomatic community: USA: 9.2M–35.6M | UK: 1.67M – 6.47M (UK) 17.7K daily
- GP visit required: USA: 4.2M-16.7M | UK: 0.76M – 3.03M
- Hospitalizations: USA: 139K-708K | UK: 25K – 128K
- Deaths: USA Pneumonia: 4K-20K | USA Circulatory: 12K–56K | UK All Complications: 13.82K
CONTRARIAN EXPERTISE
THE GREAT BARRINGTON DECLARATION
- “The Great Barrington Declaration” is signed and published in Great Barrington MA (USA) (4-Oct-2020)
- “As infectious disease epidemiologists and public health scientists we have grave concerns about the damaging physical and mental health impacts of the prevailing COVID-19 policies, and recommend an approach we call Focused Protection”
- The declaration rejects current [2020] handling of public health response to the pandemic
- By October 2021 signatories and supporters are a de facto medical alliance – the largest expert movement of its kind since the Second World War
- Great Barrington Declaration is authored by three of the world’s pre-eminent epidemiologists with key vaccine and public health expertise:
- Dr Martin Kulldorff (Harvard University)
- Dr Sunetra Gupta (University of Oxford)
- Dr Jay Bhattacharya (Stanford University Medical School)
- (plus thousands of doctors across the world at every level of medical care and research)
- NIH Directors Fauci and Collins Target the Great Barrington Declaration (18-Dec-2021)
NON-AUTHORITY DOCTOR PROTOCOLS
- FLCCC Protocols: A Guide to Management of COVID-19
- I-MASK+ Prevention and Early Outpatient Treatment for COVID-19
- MATH+ Hospital Treatment Protocols for COVID-19
- Dr Peter McCullough Early Treatment Protocol (2-Dec-2021)
- 15 Best Drug Combination Treatment Studies for COVID-19 (5-Dec-2021)
CONTRARIAN SITES
COUNTER NARRATIVE ARTICLES
- Politicization of Pandemic Measures: Dr Tess Lawrie and Ivermectin (4-May-2021)
- Canadian Covid Care Alliance: Innoculations – More Harm Than Good? (16-Dec-2021)
- WikiLeaks Expose: Council on Foreign Relations Controls Most Mainstream Media in USA (29-Jan-2018)
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study (11-Mar-2020)
- The Covid-19 Virus Double Pathogenic Mechanism. A New Perspective (8-Apr-2020)
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (28-Nov-2020)
- Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (14-Dec-2020)
- Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 (25-Jan-2021)
- World Renowned Dr Peter McCullough Blows Lid Off Covid: “Doctors Could Have Saved Thousands” (31-May-2021)
- Health Freedom Defense Fund stands by Dr. Peter McCullough (1-Aug-2021)
- The Coronavirus Pandemic – Off-Guardian
- The Free Thought Project
- The Cult of the Vaccine “The jab” is just the latest story to be reported as mantra
- Covid Call To Humanity: News from Marginalised Medical Professionals
- Did Political and Media Bias Stall the Release of Merck’s New Covid-19 Drug?
- Coronavirus Fact-Check #2: “The Emergency Powers Will Only Last 2 years!” (8-Apr-2020)
- Why are we vaccinating children against COVID-19? (16-Jul-2021)
- 30 facts you NEED to know: Your Covid Cribsheet (22-Sept-2021)
- Army to highlight future pandemic preparedness efforts at AUSA (6-Oct-2021)
- Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate (30-Nov-2020)
- VIDEO: Harvard Epidemiologist Martin Kulldorff on Vaccine Passports, the Delta Variant, and the COVID ‘Public Health Fiasco’ (10-Aug-2021)
- VIDEO: Dr Jay Bhattacharya on Vaccine Mandates, Herd Immunity, and Why Zero COVID-19 Is Impossible (28-Sept-2021)
- Aaron Siri: Scientists Sue the FDA for Data it Relied Upon to License Pfizer’s Covid-19 Vaccine (11-Oct-2021)
- Sen. Johnson for The Federalist: The Worst Is Yet To Come From Biden’s Vaccine Coercion (14-Oct-2021)
- 141 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted (17-Oct-2021)
- Dr Martin Kulldorf: A Review and Autopsy of Two COVID Immunity Studies (2-Nov-2021)
- Merck COVID Pill Approval (1-Dec-2021)
- Ivermectin – FLCCC I-MASK+ Protocol for COVID-19 (7-Dec-2021)
- Early Treatment Protocol for COVID-19: Early Treatment Can Reduce COVID-19 Hospitalizations and Deaths? (12-Dec-2021)
- Australia rules out lockdowns despite Omicron surge (21-Dec-2021)
- Scott Morrison flags changes to Australia’s COVID-19 approach after National Cabinet meeting (22-Dec-2021)
- Analysis Of Football Injury Data From 2015-2021. Are Heart-Related Injuries More Frequent In The Year 2021? (26-Dec-2021)
- Dr David Martin Reveals The Silver Bullet That’ll Strip Jab Makers Of Their Immunity (26-Dec-2021)
CONTRARIAN MEDIA
- Children’s Health Defender News & Views | COVID News | BIG PHARMA ARTICLES
- The Unity Project – Malone McCullough Great Barrington Signatories
- The Covid World Website (Covid sceptic news aggregator)
- Savage Minds Substack – Mass Propaganda Pushback
- Global Covid Summit Org
- Physicians Declaration II (29-Oct-2021)
- Original Physicians Declaration – Rome, Italy (1-Sept-2021)
- Mattias Desmet: Professor Of Clinical Psychiatry Who Studied The Psychology Of Totalitarianism: ‘This Is How We Win’ (12-Dec-2021)
- How The Koch Network Hijacked The War On COVID (22-Dec-2021)
- Rokfin: Sudden DEaths VAERS Reports Analysis
- Vaccinated More Likely To Die Based on Life Insurance Data? (9-Jan-2022)
VIDEO CONTENT
- VIDEO: Why People WILLINGLY Give Up Their Freedoms W/ Prof Mattias Desmet | YouTube Video | Aubrey Marcus Podcast (6-Dec-2021)
Peter McCullough – Children’s Health Defense – Medical Advisory
Dr Peter McCullough ‘Therapeutic Nihilism And Untested Novel Therapies’ | RUMBLE VIDEO (5-Oct-2021)
“As a now triple-vaxxed person who has had the virus previously I am intent on living my life as normally as possible, which includes not unduly worrying about it or demanding others do so. And I would argue that expecting otherwise from me would make you functionally an anti-vaxxer.”
CORPORATE STATE
Trust – Social Contract – Public Private Bioscience
Why has public trust in government/media broken down? How can it be restored?
- Why is government official guidance allowed to devolve into such useless disingenuous binaries?
- Authoritarian binaries are idiotic and destroy public faith in institutions and institutional narratives
- No party political narratives should exist in a pandemic
- Debate by public figures (not politicians) is coarsened to the point of alienation whenever political rhetoric (slogans, ad hominem, wilful misinterpretation, gotcha spin) is used instead of civil, shared truth-seeking
- Trust is shattered by god-complex celebrity front-men (like Anthony Fauci) with compromised (and even corrupt) conflict of interest (private enrichment) – personal fame is incompatible with public duty
- Vaccine versus anti-viral is a case in point. It’s not either vaccination or antiviral/alternative treatment. It’s both. It’s all of the above.
- Measures to prevent spread (testing, isolation, lockdown) and infection by SARS-CoV-2 (vaccine, antiviral) are not the same as measures to treat Covid-19 (monoclonal antibodies, fluvoximine)
- Statewide mandates restricting informed doctor-patient freedom of choice ensures both a fait accompli of outlier overdose while excluding billions (including those with no vaccine access) from best possible outcomes; not to mention demoralising the medical profession at a time it needs to be supported
- Why is there so much dehumanising rhetorical and systemic pressure on the vaccine ‘hesitant’ to comply, but never anything substantial that might cost money, like a year’s free aftercare in the event of adverse reaction?
- Fixation on compliance turns a public health choice into a loss of freedom fear, for much of the general public – why perpetuate this?
- Vaccine makers are shielded from consequences in the event of negligence – how can this help public trust?
- Why is there no quid pro quo support for workers who submit to testing and adhere to restrictions if infected (e.g. self-isolating), to cover loss of essential earnings?
- Former HHS officials say they tried to accelerate funding for what became Merck’s new “miracle” drug last year, but were blocked by the NIH
- Culture-war stupidity may have cost “tens of thousands” of lives
- Who Actually Owns Corporations Anyway? (22-Dec-2021)
- What to know about the Coronavirus and Blood Donation by American Red Cross (Aug-2021)
- “In most cases, there is no deferral time for individuals who received a COVID-19 vaccine as long as they are symptom free and feeling well at the time of donation. There is no deferral time for eligible blood donors who are vaccinated with an inactivated or RNA based COVID-19 vaccine manufactured by AstraZeneca, Janssen/J&J, Moderna, Novavax, or Pfizer”
VACCINE LIABILITY
- National Childhood Vaccine Injury Act 1986
- National Vaccine Injury Compensation Program
- United States Court of Federal Claims [vaccine court]
- THREATS AND RESPONSES: LEGAL RISKS; For Victims Of Vaccine, Winning Case Will Be Hard (14-Dec-2002)
- FOI Wales: Pfizer contract and insurance (2020)
- Contract between Pfizer and the government of Albania <may-2021)< li=””>
</may-2021)<> - Pfizer wants it, so do Serum Institute & Moderna — but what exactly is indemnity? (10-Jun-2021)
- EU Parliament Question: The Commission’s signature of a potentially unbalanced contract with Pfizer under which Pfizer has extensive rights with extremely limited liability (25-Aug-2021)
- Pfizer accused of holding Brazil ‘to ransom’ over vaccine contract demands (10-Sept-2021)
- You can’t sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government likely won’t compensate you for damages either (16-Dec-2020)
- Freedom of Information Law Suit against CDC Refusal to Provide Public Data (28-Dec-2021)
END JUSTIFIES MEANS?
- The tangled history of mRNA vaccines (14-Sept-2021)
- Can the end justify the means when it come to public health, i.e. saving the most lives versus respecting individual freedom (to be wrong)?
- What if the end is profit and the means is public health management?
- Why is an anti-viral like Ivermectin pilloried as a “horse paste” – in such a blatantly propagandist, divisive way – despite its clear usefulness as a prophylactic?
- Antivirals like Ivermectin disrupt viral replication, i.e. its effectiveness is against SARS-CoV-2 (prophylaxis) not Covid-19 (treatment)
- As SARS-CoV-2 spread it may cause Covid-19 (respiratory disease &c) which is a critical distinction
- Emphasis on antiviral as failing as a treatment is dishonest if it’s in a study or by a medical expert because they know the difference between SARS-CoV-2 virus and Covid-19 disease
- Some cite lack of quality data on anti-virals like Ivermectin as a reason for its aggressive exclusion from SARS-CoV-2 protocols.
- Why wasn’t Ivermectin trial’d aggressively from early 2020, as a repurposed antiviral against SARS-CoV-2?
- Why are there so few studies and such active suppression of repurposed drugs (cheap, readily available, proven safety record)?
- The NYT’s Partisan Tale about COVID and the Unvaccinated is Rife with Sloppy Data Analysis (1-Oct-2021)
- Let’s all Mask Up Until We Reach Herd Immunity (23-Dec-2021)
CONTRADICTIONS, SUSPENDED DISBELIEF AND HYPOCRISY
- Masks
- Funding research
- Price gouging
- Emergency Use Authorization monopoly
- Clinical trial corruption
- Breach of Nuremberg Code
- Wealth transfer from bottom to top
- Authoritarianism
- Obdurate orthodox messaging misinterpretation
BIG PHARMA – REGULATORY CAPTURE – SCALE DOMINANCE
- Why so little attention given – especially from Summer 2021 – to data showing the ad-vector vaccine antibody response is lasting considerably longer than the Pfizer/Moderna mRNA shots?
- Is the rapid loss of SARS-CoV2 neutralising antibodies (immunity) from – in particular – the mRNA vaccines contributing to the persistent and otherwise inexplicable low fidelity testing standards?
- Why is AstraZeneca vaccine not available in the US, even after its proven safe, used in comparable countries with better Coronavirus outcomes?
Is it possible for Big Pharma profit to coexist with best public health outcomes?
- Why are new technologies like vaccine development largely funded by taxpayer spending, yet all profit goes to the shareholders of the pharmaceutical corporations?
- Why is public health emergency subordinated to this upward wealth transfer profit dynamic, rather than the other way around?
- NIH Funding: Largest Source of Federal Support for Research at Rutgers U (21-May-2015)
- OSIVAX: Newly Founded French Biotech is All About Vaccines (23-Jun-2016)
- mRNA TECHNOLOGY (E-234-2016): Coronavirus Spike Proteins And Their Use (25-Oct-2017)
- 21st Century Cures Act (13-Dec-2016)
- BMJ: Pandemrix Vaccine: Why was the public not told of early warning signs? (20-Sep-2018)
- Economist Dean Baker: System Change Needed to Fight Big Pharma Price Gouging (Dec-2019)
- Pfizer CEO rallies staff to fight Democrats’ drug price negotiation (22-Sept-2021)
BIG PHARMA CORPORATIONS
- Moderna (m—-RNA) in Cambridge MA start-up launched to monetize public-private partnership
- Pfizer exclusive partnership with German funded BioNTech
- AstraZeneca licenses Oxford University developed vaccine for Coronavirus with a zero-profit agreement
PROFITS
- Big Pharma, having already entered into contracts to deliver billions of vaccine doses, spends millions on the groundwork:
- in mainstream media
- government manipulation
- health authority (CDC, FDA, NHMI, PHE, etc
- advertising
- funding studies to serve maximum profit
- guide public pandemic expectations
- Pharmaceutical corporations achieve unprecedented demand from national vaccine programs across the world
- Pfizer and Moderna (in particular) are focused on harvesting hundreds of billions of dollars profit
- Boosters and – in their ideal world – lifelong every 6-12 months compulsory vaccination equals trillions of dollars
LIMITED LIABILITY
- FOI Wales: Pfizer contract and insurance (2020)
- Contract between Pfizer and the government of Albania <may-2021)< li=””>
</may-2021)<> - Pfizer wants it, so do Serum Institute & Moderna — but what exactly is indemnity? (10-Jun-2021)
- EU Parliament Question: The Commission’s signature of a potentially unbalanced contract with Pfizer under which Pfizer has extensive rights with extremely limited liability (25-Aug-2021)
- Pfizer accused of holding Brazil ‘to ransom’ over vaccine contract demands (10-Sept-2021)
- You can’t sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government likely won’t compensate you for damages either (16-Dec-2020)
TRILLIONS
- Trillions of dollars are at stake
- Spread of revenue for business, corporations, health regulators and government/treasury
- Lion’s share of revenue heading for Wall Street and City of London shareholders in big pharma
- Medicine hegemony in the United States, the UK and India (as the biggest vaccine manufacturer)
- This hegemony of profit-share will ensure American/UK govt and its corporate clients will continue to exert their tight hold on the Coronavirus regulation (ppatents) on behalf of pharmaceutical corporations (profit engines) and health authorities (funding distributors) coordinated by Gates Foundation/Wellcome Trust (source of over 60% global money in all medical and biotech)
COST/PRICING
- Remdesivir: 340UKP Dose Cost in the United Kingdom
- Vaccines and Related Biological Products Advisory Committee meeting to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older
- Comirnaty vs Pfizer Vaccine – Legally Distinct
INSURANCE AND SICK LEAVE
- Profit Squeeze and Cost Distribution For and Against Vaccine Hesitant and Covid-19 ‘Freeloaders’ (28-Aug-2021)
- “Delta’s Extra $200 Monthly Healthcare Surcharge To Unvaccinated Airline Workers May Have Serious Unintended Consequences, according to the pro-corporate forbes.com website”
- Cost-sharing waivers and premium relief by private plans in response to COVID-19 in the Early Pandemic (19-Nov-2020)
- Will My Health Insurance Cover a COVID-19 Vaccine? (29-Aug-2021)
- Reddit: The Days of Full Covid-19 Insurance Coverage Are Over (20-Sept-2021)
- H.R.1319 – American Rescue Plan Act of 2021
- Coronavirus sick pay scheme opens for applications
- CORONAVIRUS / COVID-19: KEEPING PDX PEOPLE HEALTHY AND INFORMED (27-Aug-2021)
- FACT SHEET: Federal Coronavirus Paid FMLA, Sick Leave Requirements (3-Nov-2021)
- USA Employment 2021 Assessment (7-Sept-2021)
- US PAID SICK LEAVE, SCHOOL CLOSURE, WORKPLACE CLOSURE, AND QUARANTINE LEAVE LAWS (2-Aug-2021)
- “ANTICIPATION is a question of fact, and a jury determination of anticipation is reviewed for substantial evidence. Acromed Corp. v. Sofamor Danek Grp., Inc., 253 F.3d 1371, 1378–79 (Fed. Cir. 2001). Under pre-AIA § 102, one way in which a patent is anticipated is where “the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States…” 35 U.S.C. § 102(b) (2000). Public use under pre-AIA § 102(b) includes any use of the claimed invention by a person other than the inventor who is under no limitation, restriction or obligation of secrecy to the inventor. Netscape Commc’ns Corp. v. Konrad, 295 F.3d 1315, 1321 (Fed. Cir. 2002).”
VACCINE DATA – TRIALS – EFFICACY – APARTHEID
Development of mRNA technology has been in progress for over 20 years, primarily with a view to opening a new deliver mechanism and drug potential for cancer treatments. Various science hurdles had to be overcome; and NIH / DARPA funding drove the research in the US. UK and German government funding equivalents, both importing the technology once the patented messenger RNA delivered in lipid shell mechanism was patented by US Govt. NIH licensed the mRNA tech to public/private companies like BioNtech, Moderna, Cellscript and others.
While mRNA was originally found to be viable for in vivo gene transfer in the early 1990’s, the development of mRNA vaccines was initiated much later due to the inherent instability of mRNA compared to DNA. The efficacy of mRNA vaccines can be increased by several factors, such as ensuring mRNA purity, adding 5’ Kozak and cap sequences, 3’ poly-A sequences and modified nucleosides to increase mRNA stability and decrease detection by the receptors of innate immune cells, codon optimization, introduction by intramuscular, and intradermal injection to reduce RNA degradation, and by generating thermostable mRNA. Methods to encapsulate RNA have also been explored to increase the stability and immunogenicity of RNA vaccines, as has been used with exosome encapsulated RNA and RNA-transfected dendritic cells. When fully optimized, RNA vaccines may have an immunogenic advantage over DNA vaccines due to the presence of multiple cellular pathways that activate innate immunity in response to foreign RNA such as the toll-like receptors (TLRs) and RIG-I-like receptors (RLRs).
CLINICAL TRIALS
- Why did initial Pfizer/Moderna/AZ interim press releases define vaccine efficacy with no follow-up, no reference to time scale?
- Why have none of the Big Pharma corporations carried out (or published) ongoing analysis of vaccine efficacy – using the trial subjects?
- Why were the claims of 98%, 95%, 90% efficacy published across the world based on a press release; with no follow up publication of publicly accessible trial data a year after EUA?
- Why have the vaccine trials and subsequent study data been concealed from peer-review? Why is this legal?
PHASE 3 EFFICACY (NOV-DEC 2020)
- Pfizer and Moderna showed almost 100% efficacy in press release on abridged phase III trials but real world data revealed much lower efficacy and – after 3-6 months – rapidly decreasing antibody titers
- Why is the less rapid cliff-edge degradation of non-mRNA vaccines not part of the public conversation?
- Phase III trial efficacy percentages were extrapolated from, ultimately, just a few dozen cherry-picked subjects and never fully published data
- How does vaccine efficacy factor in time and viral load, i.e. spending more time coming into contact with SARS-CoV2, being exposed to higher viral load?
- Vaccine trials pre-published their efficacy numbers after a few weeks phase 3 test subject data
Why were there no follow-up on those subjects involved in the various phase 3 trials, no ongoing testing status?
- Why, almost two years into the pandemic, are the same dysfunctional protocols and the same incomplete data still the best publicly available?
BOOSTERS?
- Immunity is a spectrum – a multivariate marker set involving many types of cells (e.g. T-cells, B-cells, etc)
- Antibodies wane over time
- Studies of immunity levels won’t be complete if only focused on certain antibodies while omitting the key longer term memory markers for immunity
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- Serascreen: COVID-19 Vaccine Effectiveness Test
- YOUTUBE: video on vaccine data analysis
“Is there genuine vaccine apartheid in rich versus poor nations? If so, why isn’t anyone breaking the paradigm? Why isn’t self interest in beating pandemic variants should motivation enough?”
See COVID-19 VACCINE TRACKER (by country)
Pfizer/Moderna (i.e. NIH patent holder) is not sharing vaccine recipe to protect the mRNA platform – separate to the whole Coronavirus pandemic. The mRNA platform has potential for revenue streams that dwarf the billions in profit from SARS-CoV-2 e.g. it has myriad uses as a cancer delivery drug, which is perhaps the biggest prize in medical science – a bonanza of incalculable trillions that could roll on and on for decades. This is why the patent isn’t going to be shared. It won’t be shared until the technology can be shared in a way that doesn’t open access beyond targeted Coronavirus usage. The vaccine corporations will doubtless be working on a nerfed version. If they find it, there will be a fanfare of “patent sharing”. Gates Foundation (USA) and Wellcome Trust (UK) are key players in this global strategy.
VACCINE APARTHEID
- Scientific/academic research and all corporate media/mainstream politics is funded (captured) by the interests of the Gates Foundation and the Wellcome Trust – between them controlling over 60% of funding worldwide
- Vaccine distribution is mostly under the control of the US (mRNA), the UK (Oxford-AstraZeneca) and India (AstraZeneca), with Russia and China rolling out their own vaccines using homegrown technology
- US Govt controls Pfizer/BioNtech and Moderna patents through Bayh-Doyle Act because as with over 90% of drug/interventions on the market, the NIH managed the funding of their development including the all-important underlying mRNA technology
- Oxford University’s Vaccintech spinoff owns the AstraZeneca IP/patent and AstraZeneca is a UK/Swedish corporation so UK government will have a decisive role in sharing (or not) ad-vector patents
- US public health authorities (NIH, BARDA, CDC, FDA) are directed by the Gates Foundation
- UK public health authorities (UKHSA, NICE) are directed by the Wellcome Trust
- EU and India have significant roles in production but probably less relevant in patent control despite BioNtech being a German publicly funded research company
- India is a major vaccine producer but its nationalist government has expelled the vaccine maker CEOs, hoarding stock for its own people; whose need is great
- USA and UK are the only autonomous advanced vaccine ecosystems
- US publishes speeches about benevolent provision but meanwhile aggressively defends conditions of price gouging and monopoly of Pfizer and Moderna over mRNA vaccine tech
- USA and UK have both horded homeland stock
- Brookings Institute: Cash and the City – COVID-19 digital social response in Kinshasa, DRC (8-Sept-2021)
- Covax Misses its 2021 Delivery Target: What’s Gone Wrong in the Fight Against Vaccine Nationalism? (18-Sept-2021)
- Seguro Popular: Health Coverage For All in Mexico (26-Feb-2015)
- Cuba Sends 120,000 COVID-19 Vaccines to Syria (9-Jan-2022)
DOCUMENTS
- WAIVER FROM CERTAIN PROVISIONS OF THE TRIPS AGREEMENT FOR THE PREVENTION, CONTAINMENT AND TREATMENT OF COVID-19 (2-Oct-2020)
- Members discuss TRIPS waiver request, exchange views on IP role amid a pandemic (23-Feb-2021)
- Statement from Ambassador Katherine Tai on the Covid-19 Trips Waiver (5-May-2021)
- U.S. Says It Supports a Covid Vaccine Patent Waiver, But Document Reveals It Is Dragging Feet at WTO (15-Sept-2021)
- WTO postpones major meeting after new variant outbreak (26-Nov-2021) [Zoom, anyone?]
- WTO General Council decides to postpone MC12 indefinitely (26-Nov-2021)
- U.S. President Biden calls for intellectual property protection waivers after Omicron discovery (27-Nov-2021)
- Documents Reveal Biden Admin Not Fighting for a Covid Vaccine Patent Waiver, Despite Public Statements (29-Nov-2021)
- Lord Mountbatten’s Last Supper to Public Health’s Last Rites – The Trajectory of Medicine (31-Oct-2019)
- NIH funding and the pursuit of edge science (19-May-2020)
- Reinvigorating comprehensive primary healthcare is the way to resolve declining doctor-patient relationship (30-Sept-2020)
- The COVID-19 insidious trick: Subjective perception of numbers (29-Nov-2020)
- COVID-19 (SARS-COV-2): Transformations in medicine, our existence, and world order?
- Methods to support evidence-informed decision-making in the midst of COVID-19: creation and evolution of a rapid review service from the National Collaborating Centre for Methods and Tools
- Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures (19-Mar-2020)
- The Organic Turn: Coping With Pandemic and Non-pandemic Challenges by Integrating Evidence-, Theory-, Experience-, and Context-Based Knowledge in Advising Health Policy
- Impact of the COVID-19 pandemic on publication dynamics and non-COVID-19 research production
- Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators (29-May-2021)
- The first 10 000 COVID-19 papers in perspective: are we publishing what we should be publishing? (20-Aug-2020)
- Forecasting for COVID-19 has failed (25-Aug-2020)
- Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination (5-Jan-2022)
VACCINE PRICING
- Given all the talk about poorer countries and vaccine availability, why is it left to non-mRNA vaccines to cover most of the developing world’s supply? Why is there media silence on this?
- Does the public even know about the relative vaccine per-dose cost? Does that add up, vis-a-vis authentic public discourse?
- Doctors Without Borders Slams U.S. for Hoarding 500 Million Vaccine Doses (11-Oct-2021)
- Moderna’s founders make their debut on the Forbes top 400 richest people in America (7-Oct-2021)
- Healthcare Access and Quality Index – Healthspan Mortality in 195 countries (1990–2015)
- HEALTHLINE.COM: Does Mexico Have Better Healthcare Than the United States?
- CDC Census: Life Expectancy in the United States for 2018
- New geoblocker introduced to UK NICE (National Institute for Health and Care Excellence) website
NOTES
- an in silico experiment is one performed via computer simulation – as opposed to in vitro et al. It’s pseudo-Latin for in silico
ANTIVIRALS – MONOCLONAL ANTIBODIES – ACE2/PROTEASE INHIBITORS
QUESTIONS
- Why is Merck putting billions into researching Molnupiravir patented antiviral without putting any resources into studies or proliferating proven safe Ivermectin off-patent antiviral with potential for repurposing against Covid-19?
- Pharmaceutical companies are about business and profit, quite legitimately
- Why is government not promoting existing treatments or funding studies – monoclonal antibodies, antiviral drugs (prophylaxis and/or treatment), etc – as a public health duty?
- Why is government using its authority to push censorship in line with pharmaceutical company profit monopoly including making a fait accompli of emergency use authorisation and maximum profit from patent over off-patent generics?
- How can protecting corporate (big pharma) profit be more important than safeguarding human life in public health (government) decision making – funding – protocols – authorisations – recommendations – messaging – policy?
- Merck, developer of general antiviral Ivermectin, announcing late stage human trials for a “new” patent medication and oral antiviral drug for COVID-19 (24-Sept-2021)
- “Vioxx” is the name is a smear campaign playbook used by Merck Pharmaceuticals to campaign against its own competing drug—the FDA-approved, Nobel prize-winning antiviral Ivermectin, which is generic, cheap and globally available with very little scope for significant profit
- Merck’s deadly Vioxx playbook redux (7-Sept-2021)
WORLD HEALTH
- There are still many nations where vaccines are not yet widely available.
- There is a gradual shift in focus, to antiviral drugs.
- Two ways to get new drugs:
- Develop novel antiviral drugs for SARS-CoV-2
- Repurpose existing FDA-approved drugs to treat COVID-19
- ANTIVIRAL NOTES
- Ivermectin (by Merck Pharmaceuticals) is the most studied “repurposed” medication globally in randomized clinical trials, retrospective studies and meta-analyses
- Molnupiravir and Ivermectin have both demonstrated adjunctive chemoprophylaxis
- No profit from generic off-patent Ivermectin
- Funding from Merck (originally from NIH public funding) directed on:
- New patented medication
- Marketing Molnupiravir
- Buying FDA-simpatico studies demonstrating Molnupiravir efficacy
- Greasing the public health wheels for authorisation e.g. in the UK, US, EU, etc
NIH EVASION: IVERMECTIN / MONOCLONAL ANTIBODIES
Much media propagation of the NIH having concluded “there’s currently insufficient data to recommend ivermectin for the treatment of COVID” i.e. don’t use it, don’t explore it. In fact, NIH current status on Ivermectin is there is not enough data to recommend or to discourage its use. NIH recommendation prior to December 2020 was to discourage Ivermectin usage. The change itself is significant and would usually be accompanied by a rush of funds to study its antiviral efficacy. No such funding has been forthcoming.
Interestingly, two other COVID modalities have exactly the same recommend/discourage status. That would be remdesevir and outpatient monoclonal antibodies. EXACTLY the same status on both of these as ivermectin currently. The NIH states there is not enough evidence to recommend or to discourage the use of either of these. And yet we continue right on with both the others without a blink of an eye.
A little maths –
- Ivermectin course for COVID is less than twenty dollars.
- A course of REMDESEVIR is currently right at 8800 dollars.
- An outpatient treatment with monoclonal antibodies is right at 23000 – 25000 dollars with all the infusion costs added.
Eventually, if things keeps looking, smelling and tasting like shit then we have to conclude it is shit.
ONGOING TRIALS
- Molnupiravir (Merck)
- new prodrug antiviral developed by Merck Pharmaceuticals
- currently in the pipeline for authorisation as a SARS-CoV2 prophylaxis and treatment
- active treatment of new SARS-CoV-2 infections
- post-vaccination breakthrough COVID-19 cases
- authorised in the UK, applications pending USA and Europe
- Ritonavir (Pfizer)
- Phase 2/3 trials early completed
- applying for authorisation
PHARMODYNAMICS
- “Molnupiravir is a pro-drug of the novel active antiviral nucleoside analogue … It’s a broad spectrum antiviral agent. … Ivermectin is a broad-spectrum, anti-parasitic, antibiotic and which has demonstrated broad-spectrum antiviral activity”
- Molnupiravir is a broad spectrum antiviral agent against SARS-CoV-2, SARS-CoV, seasonal or pandemic influenza and MERS coronavirus
- Ivermectin is an FDA-approved, WHO essential drug used as broad spectrum antiparasitic, antibiotic, and which has demonstrated broad spectrum antiviral activity against RNA viruses, including HIV, Zika, MERS and Coronavirus
- FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
- 5000-fold inhibition of SARS-CoV-2, (99.98% at 48 hours)
- The inhibitory concentration IC50 of Molnupiravir shows it to be an even more potent anti-SARS-CoV-2 agent, compared to Ivermectin in vitro
- Both Molnupiravir and ivermectin are well absorbed after oral dosing
- Tmax of Molnupiravir being 1-1.75 hours, with a half life of 7 hours
- Tmax of Ivermectin is 4-6 hours, very long half life of 81-91 hours
- Ivermectin, being lipophilic has a large volume of distribution
- Ivermectin has the ability to accumulate in the lungs where SARS-CoV2 is most dangerously concentrated
- Anti-SARS-CoV-2 actions of Molnupiravir and Ivermectin are dose and concentration dependent
- Molnupiravir active metabolite (NHC-5 Triphosphate) acts as a competitive alternative substrate for viral RNA
causing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication - There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells
- Ivermectin, multifarious actions, binding to SARS-CoV-2 spike protein, reducing cell entry via human ACE2 receptors, reducing viral transcription
- Complimentary pharmacokinetics and pharmacodynamics of the drugs may be additive or synergistic.
- This should be further investigated in anti-SARS-CoV-2 antiviral combination therapy e.g. a combination of Molnupiravir with Ivermectin putatively, in effects on RdRP or cytokine release
COST COMPARISONS
- Cost of Ivermectin package of 100 tablets of 3mg is $2.96, e.g. 12mg per day for 5 days = $0.53
- Cost of Molnupiravir to be negotiated separately with national health services but US govt initial purchase worked out at $700 for the equivalent 5 day course
ARTICLES
- The molecular basis for public T-cell responses? (Mar-2008)
- Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein (9-Apr-2020)
- Continued Effectiveness of COVID-19 Vaccination among Urban Healthcare Workers during Delta Variant Predominance (16-Nov-2021)
- Pathways to Resistance: HCV Protease (2010)
- Principal Investigators (Funding Gatekeepers)
- What makes an equation beautiful? (14-May-2014)
- Spike Mutations – Potential Implications for Vaccine T Cell Responses
- Site-specific analysis of the SARS-CoV-2 glycan shield (28-Mar-2020)
- Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses (26-Aug-2020)
- Computational epitope map of SARS-CoV-2 spike protein (1-Apr-2021)
- SARS-CoV-2 variants: levels of neutralisation required for protective immunity (13-Aug-2021)
- Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? (17-Aug-2021)
- Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (29-Apr-2021)
- Lab reveals how an oral antiviral drug confuses the replication machinery of SARS-CoV-2 (11-May-2021)
- Had COVID? You’ll probably make antibodies for a lifetime (27-May-2021)
- Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain (12-Oct-2021)
- Arkansas inmates say they weren’t told they were treated for COVID-19 with ivermectin (2-Sept-2021)
- No fresh Covid cases in UP’s 59 districts; Australian MP praises Yogi govt use of Ivermectin (14-Sept-2021)
- The Snake-Oil Salesmen and the COVID-Zero Con: A Classic Bait-And-Switch for a Lifetime of Booster Shots (Immunity as a Service) (2-Sept-2021)
- Lessons From The Ivermectin Debacle (8-Sept-2021)
- Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 (14-Oct-2021)
MOLNUPIRAVIR
- Cambridge Bioscience: EIDD-2801 (Molnupiravir) 5mg – Available UK and Ireland
- DrugBank: Molnupiravir is an orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19
- The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) (28-May-2020)
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) (5-Oct-2020)
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2 (19-Apr-2021)
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template (29-Apr-2021)
- Molnupiravir, an Oral Antiviral Treatment for COVID-19 (17-Jun-2021)
- Australian Government Restricts Doctor Prescribing Ivermectin Antivirals (10-Sept-2021)
- Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study (1-Oct-2021)
- Merck says COVID-19 pill cuts risk of death, hospitalization (2-Oct-2021)
- Toward a Practical, Two-Step Process for Molnupiravir from Cytidine (11-Jan-2021)
- Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine (8-Apr-2021)
- Toward a Practical, Two-Step Process for Molnupiravir: Direct Hydroxamination of Cytidine Followed by Selective Esterification (28-Jul-2021)
IVERMECTIN
- Crystal Structure of the Full-Length Japanese Encephalitis Virus NS5 Reveals a Conserved Methyltransferase-Polymerase Interface (Aug-2013)
- PDF: Molnupiravir versus Ivermectin
- vermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes (3-Jan-2021)
- Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents (20-Jan-2021)
- Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach (25-Mar-2021)
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 (22-Apr-2021)
- Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection (30-Jun-2021)
- Peer-Reviewed) Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays (1-Nov-2021)
PAXLOVID (RITONAVIR)
- Pfizer’s new antiviral PAXLOVID (PF-0732133)
- All Hands on Deck as Scientists Revive SARS Protease Inhibitor to Attempt to Fight COVID-19
- Protease Inhibitors to Fight COVID-19: Stopping the Virus’s Life Cycle
- Pfizer Initiates Phase 1 Study Of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 (23-Mar-2021)
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 (22-Apr-2021)
- Pfizer Starts Global Phase 2/3 EPIC-PEP Study Of Novel COVID-19 Oral Antiviral Candidate For Post-Exposure Prophylaxis In Adults (27-Sept-2021)
- Ritonavir (C₂₃H₃₂F₃N₅O₄) is designed to block activity of the SARS-CoV-2-3CL – protease inhibitor targeting 3CL (main protease, i.e. 3CL Mpro – Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)
- PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY (5-Nov-2021)
ANTIVIRAL DRUG DEVELOPMENT
- clinicaltrials.gov: Search Results and Latest Published/Pre-Published US Clinical Trials – Meta Search: Ivermectin + Covid-19
- Rick Bright – Merck – BARDA – Dr Cadlich – Cronyism
- Molnupiravir – HHS official documents – Emergency use authorisations for vaccines
- Ridgeback Pharma funding – Delayed development – Merck buying up Ridgeback’s Molnupiravir after sidelining Ivermectin
- FDA authorisations for mRNA vaccine factor | Merck with billions in the balance
- YOUTUBE: Antivirals, Ivermectin, Molnupiravir Evaluated
- Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020)
- Activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds
- Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents (20-Jan-2021)
- Out of 13 OTDs only ivermectin completely blocked (more than 80%) of 3CLpro activity at 50 µM concentration
- Development, validation, and approval of COVID-19 specific drugs takes years
- Drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly
- Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 (25-Jan-2021)
- With SARS-CoV-2 S Spike protein: Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2
- In agreement to our findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor
- Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein): Docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions
- Binding Interactions of Selected Drugs With Human ACE-2 Protein: Ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions
- With SARS-CoV-2 S Glycoprotein: Ivermectin showed the highest binding affinity to the predicted active site of the protein
- With SARS-CoV-2 Nsp14 Protein: Ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions
- Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro: Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions
- Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach (25-Mar-2021)
- Ritonavir, C37H48N6O5S2 | Ivermectin, C48H74O14
- Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach
- Documented intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6
- PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease
- Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study (22-Jul-2020)
- From the docking analysis, Ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds
- Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1
- Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection (30-Jun-2021)
- strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket
- Risk of virus developing resistance to PF-07321332 means Pfizer’s proposed antiviral could be resisted whereas Ivermectin works on many levels
- If Pfizer wanted to create a short-lived expensive patent medication that’d need a new patent medication as a perpetual profit opportunity for Pfizer
- Antiviral performance of graphene-based materials with emphasis on COVID-19: A review (31-Mar-2021)
IVERMECTIN MESSAGING
- Why ivermectin should not be used to prevent or treat COVID-19 (2-Sept-2021)
- Covid antiviral pill can halve risk of hospitalisation (1-Oct-2021)
- Ivermectin: How false science created a Covid ‘miracle’ drug (6-Oct-2021)
- American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) Strongly Oppose the Ordering, Prescribing, or Dispensing of Ivermectin (ama-assn.org website)
IVERMECTIN STORY
- Antiviral medication Ivermectin was invented in Japan and mass-produced by Merck
- Ivermectin is now out of patent, cheap and available worldwide
- Merck is developing Molnupiravir (MK-4482) as a therapeutic to treat COVID-19 infections
- Molnupiravir would be an antiviral, like Ivermectin, but patented and therefore potentially worth tens of billions profit versus Ivermectin which is worth nada
- Molnupiravir is in/recently finished Phase 3 trials
- Merck received a base award amount of $1.2 billion on 7-Jun-2021 from the Federal Government (1.7 million doses)
- Molnupiravir is authorised by the UK health authority with authorisation pending in US FDA, EU, Canada and other cracker countries
- Not surprisingly, Molnupiravir and Ivermectin – both antivirals – have certain similarities with neither showing any serious adverse side effects
- Merck had the patent on Ivermectin until 1996
- Molnupiravir has been funded by the US taxpayer (through BARDA) and is on-patent
- The difference in profit potential may explain why there is so much disparagement of Ivermectin
- Ivermectin shut out and Molnupiravir widely accepted equals billions USD profit to Merck
- What I cannot grasp is that for the 10 months when the vaccines were being developed, certain caring, critical care physicians sought out existing drugs and developed protocols
- Prophylaxis, treatment and containment protocols have been changed many times especially with each new variant
- The FLCCC Alliance recommends the use Ivermectin as part of more expansive protocols for prophylaxis and treatment of COVID-19 (at all stages) vaccinated or unvaccinated
- Physicians in the FLCCC Alliance are vilified in the mainstream media but they should be applauded
AUTHORITARIAN AUSTRALIA
- Australian government pronounces on Ivermectin via new Australia Medical Association rules for all doctors
- AMA rules specifically target doctors, restricting their prescribing, rather than citizens who may be buying antivirals on the black market
- I doubt this new ruling will reduce illegal Ivermectin import
- If anything the AMA dictates will push doctors and patients further apart, making the latter more likely to resort to self-prescribing, more likely to use social media for dosages, causing worse outcomes
- Medically honest policy would’ve been to encourage the doctor-patient relationship by not mistrusting the medical experts and not alienating the patients
- Freeing doctors to do what they’re trained to do saves lives
- Good doctors are likely to nurture trust in vaccines (by recommending them) while prescribing antivirals or other additional interventions as/when appropriate
- CHANGE OF POLICY?
INFORMATICS
HEALTH AUTHORITIES
NIH (National Institute of Health)
NIST (National Institute of Standards and Technology)
CDC (US Center for Disease Control)
UKHSA (UK Health Security Agency)
EIC (European Innovation Council)
Bill and Melinda Gates Foundation (US Healthcare Charity)
WELLCOME TRUST (UK Foundation)
NIAID (National Institute of Allergy and Infectious Diseases)
BARDA (Biomedical Advanced Research and Development Authority)
GLOBAL CORONAVIRUS CLINICAL TRIALS
WHO: Therapeutics and Covid-19: Living Guideline
GAVI: Global Vaccine Alliance
CDC: Latest Vaccine Price List
Doctors Laboratory: Coronavirus Covid-19 PCR/Antibody Testing
BCDCC Canada: Covid-19 Vaccine Safety
Oxford Com-Cov: Oxford Vaccine Group’s Com-Cov Combination Tracking
Covid-19: Vaccine Tracker (Candidates, Trials, Approvals)
GOVERNMENT AGENCIES
- NIH: Vaccine Types | Vaccine Report (Jun-2021)
- NIST.GOV: Bayh-Dole Regulations | Wikipedia – Bayh-Dole Act
- NIAID: Funded Research News | Response to COVID-19
- NIAID: Developing Therapeutics and Vaccines for Coronaviruses
- US MILITARY: AUSA (Association of the United States Army), Annual Meeting and Exposition
- Combat Infectious Diseases Research Org | National Guard Covid Response
HETERODOX TRACKERS
- Trial Site News | Tech Outsourcing
- COVID-19 Early Treatment – Real-Time Tracker | Protocols
- ivmmeta.com – Ivermectin (Antivirals) Covid-19 Data Tracker
- KEI – Coronavirus Index | Contracts Tracker
- Critical Care Alliance (FLCCC) | COVID-19 Protocols
- UK COLUMN: Counter News Org
- Doctors for Covid Ethics Org
ORTHODOX TRACKERS
- GLOBAL: GISAID – Coronavirus Variant Tracker
- UK: COVID-19 | NHS Capacity | DAILY VACCINATIONS
- KFF: COVID-19 Vaccine Use and Reactions Monitor
- SeroTracker Map: Global Seroprevalence Tracking Dashboard
- NIKKEI: GLOBAL COVID-19 Vaccinations Tracker
- WHO Databases: VigiBase | VigiAccess
NATIONAL GUIDELINES
- COVID-19 Rapid Guideline: Managing Covid-19 (UK NICE)
- Therapeutic Management of Nonhospitalized Adults With COVID-19 (USA NIH)
- Therapeutic Management of Hospitalized Adults With COVID-19 (USA NIH)
- A Guide to Home-Based COVID Treatment (28-Aug-2021)
R & D
BIG PHARMA
- Pfizer Inc
- AstraZeneca PLC
- BioNTech SE GmbH
- Medicago Inc (Canada PPC)
- Imaxio – OsiVax (France)
- Merck Pharmaceuticals
- Moderna Therapeutics
- Vaccitech (Oxford)
- 27 Years Pharma Industry Criminal and Civil Penalties (1991-2017)
- Health Care Lobbyists Admit Their Big Scam (11-Oct-2021)
- You’re Being Gouged On Medicine You Already Paid For by David Sirota (12-Oct-2021)
SCIENTISTS
- Katalin Karikó
- Robert Malone
- Direct Gene Transfer into Mouse Muscle in Vivo (23-Mar-1990)
- Kayvon Modjarrad
- EID Research: Bio | US Military: Walter Reed Army Bio
- Jason McLellan Biologist
- Patents 2015-2016
- McLellan Lab (University of Texas Austin)
- Rick Bright | CEO Pandemic Prevention Rockefeller Foundation
- Chris Butler MD FMedSci
- University of Oxford, Primary Care Professor
- Dr Barney Graham (NIAID)
- Dr Michael Mina (Harvard T. H. Chan School of Public Health)
- Dr Peter Duesberg UC Berkeley Molecular Biologist | HIV/AIDS Homepage
- Dr Janet Woodcock FDA Commissioner | @DrWoodcockFDA Twitter
- Mattias Desmet (Ghent University) | Savage Minds Substack
OPEN DATA
- Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak (31-Jan-2020)
- Taxpayer Funded Research And The Covid-19 Vaccine (31-Mar-2021)
UNDERBELLY
- USA v Pfizer – Anti-Kickback Criminal Court Settlement (20-May-2018)
- Pfizer Corporate Integrity Agreement with Dept Health and Human Services (22-May-2018)
- Complaint v CDC (29-Jul-2021) | Reply to FDA (21-Oct-2021) | OHSA Supreme Court Brief Testing and Mandates (5-Nov-2021) | OSHA Petition – Multiple Business v US Govt (Dec-2021) | Pfizer FDA LOA Booster Shot Bullshit (3-Jan-2022) | FOI v FDA (6-Jan-2022)
- Origins of COVID-19: Fauci’s $191 Billion Bio-Weaponization of Viruses Against Humanity (21-Jun-2021)
- Bacterial Pneumonia Caused Most Deaths in 1918 Influenza Pandemic (19-Aug-2008)
- IDSA says US antiviral supply for flu falls far short (17-Jun-2005)
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (22-Aug-2005)
- Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy (16-Mar-2021)
- Operation Choke Point (Obama-era)
- Operation Choke Point reveals true injustices of Obama’s Justice Department (7-Nov-2018)
- Probe of Secret Vaccine Talks Finds ‘Access for All Was Never a Priority’ (24-Sept-2021)
- Biohacker’ Who Injected Himself With DIY Herpes Treatment Found Dead (5-May-2018)
- Covid-19: A Vaccine For Us All? (May-2020)
- European Parliament: Questions about Contracts with Pfizer and Moderna (28-Apr-2021)
- Pfizer avoids taxes via the Netherlands and makes a profit worth billions (15-May-2021)
- How to Make Enough Vaccine for the World in One Year (26-May-2021)
- BioNTech alone could lift German economy by 0.5% this year (10-Aug-2021)
- Report: Pfizer and Moderna raise vaccine prices for EU (2-Aug-2021)
- EU negotiators defend high Covid vaccine prices paid to pharma (23-Sept-2021)
- Public Readiness and Emergency Preparedness Act (PREP) (4-Oct-2021)
- Note 1. Pursuant to 42 U.S.C. § 247d-6d the federal government “Declaration pursuant to section 319F-3 of the Public Health Service Act to provide liability immunity for activities related to medical countermeasures against COVID-19” provides that “manufacturers” of “any vaccine, used to treat, … prevent or mitigate COVID-19” shall enjoy “[l]iablity immunity ,” including, “from suit and liability under Federal and State law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or the use by an individual of a [COVID-19 vaccine].”
- Note 2. Pursuant to 42 U.S.C. § 247d-6d(c)(5) “If an act or omission by a manufacturer or distributor with respect to a covered countermeasure, which act or omission is alleged under subsection (e)(3)(A) to constitute willful misconduct, … such act or omission shall not constitute ‘willful misconduct’ … if—(i)neither the Secretary nor the Attorney General has initiated an enforcement action with respect to such act or omission; or (ii)such an enforcement action has been initiated and the action has been terminated or finally resolved without a covered remedy.
GRIFT
-
DEFUSE PROJECT (22-Sept-2021)
“Archive exposing timeline of gain-of-function circumvention of laws, appropriation of public funds, US-China secret collaboration and pandemic mishandling”
-
GAVI VACCINE (25-Aug-2021)
“Scientists around the world are working to produce vaccines that can stop COVID-19 | since the emergence of this novel coronavirus in Dec 2019, 20 vaccines have started to be rolled out in countries worldwide”
-
BBC: TRUSTED NEWS INITIATIVE (10-Dec-2020)
“Trusted News Initiative (TNI) brought to bear on news and internet media outlets, directed by government, ostensibly to combat so-called disinformation”
-
NIH: NIH VACCINE (25-Jun-2020)
“NIH has played a critical role in coronavirus research for decades. Federal scientists have helped fund, design, patent and test mRNA-1273 and others; vaccine candidates developed through Moderna and licensed to BioNTech (Germany) partnered with Pfizer Inc”
-
Gain Of Function (19-Dec-2017)
“National Institutes of Health (NIH) today lifted a 3-year moratorium on funding gain-of-function (GOF) research on potential pandemic viruses such as avian flu, bat coronavirus, SARS, and MERS, opening the door for gain-of-function research to resume”
-
Coronavirus Spike Protein (13-Oct-2017)
“Prefusion Coronavirus Spike Proteins NIH document – exemplar of going through the motions of appropriating the govt-funded mRNA vaccine technology and corollary patents, to enrich private business interests”
-
Leading US Causes of Death 1999-2014
“Studying the data about leading causes of death in metro and nonmetro areas of the United States 1999 and 2014 inclusive. Higher rates of death in nonmetropolitan areas (often referred to as rural areas) compared with metropolitan areas have been described”
-
21st-Century CURES Act (13-Dec-2016)
“The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently – Ahem”
-
ACA Rural Health Insurance (29-Mat-2014)
“Almost 50 million people (16%) population of the United States, live in rural areas, mainly low-to-moderate-income individuals. 65% of uninsured in rural areas live in States without ACA coverage”
-
Oxford Vaccine Docs Repository (Mar-2020 to Feb-2021)
“Small repository of documents and links relating to the Oxford University SARS-CoV2 vaccine and Bill Gates Foundation early negotiations”
-
ECOHEALTH ALLIANCE (2014-2019)
“Ecohealth Alliance Inc (Peter Daszak) ongoing provision of research grant payments for Bat Coronavirus Gain of Function work at the Wuhan Institute of Virology”
-
Dr Peter Daszak (2010-2021)
“Anonymous “Conspiracy” Dossier on Coronavirus SARS-COV2, Peter Daszak Wuhan Virology, Fauci, the NIH/DARPA/Chinese CP Research Timelines”
-
Impact of Health Insurance on Vaccination Coverage (15-Apr-2015)
“Underinsurance has been a barrier to vaccination among children. Information on vaccination among adults ≥18 years by insurance status is limited |Purpose: To assess vaccination coverage among adults ≥18 years in the United States in 2012 by health insurance status and access to care characteristics”
-
Truman v AMA (16-Jul-1947)
“The Challenge of National Healthcare as President Truman takes on the American Medical Association in the aftermath of World War II”
-
The Nuremberg Code (1947)
“The judgment by the war crimes tribunal at Nuremberg laid down 10 standards to which physicians must conform when carrying out experiments on human subjects in a new code that is now accepted worldwide.
This judgment established a new standard of ethical medical behaviour for the post World War II human rights era. Amongst other requirements, this document enunciates the requirement of voluntary informed consent of the human subject. The principle of voluntary informed consent protects the right of the individual to control his own body.
This code also recognizes that the risk must be weighed against the expected benefit, and that unnecessary pain and suffering must be avoided.
This code recognizes that doctors should avoid actions that injure human patients.
The principles established by this code for medical practice now have been extended into general codes of medical ethics.”
-
AMERICAN RESCUE PLAN ACT OF 2021 – HARDCOPY
-
The Medical and Scientific Conceptions of Influenza (stanford.edu)
-
IRS: Amounts Paid for Certain Personal Protective Equipment Treated as Medical Expenses (Jul-2021)
BIOSECURITY
- The Ride of the Biosecurity State – with Whitney Webb (20-Sept-2021)
- Edinburgh University – Ferritin Family Proteins and Bionanotechnology (2015)
- Environmental Biodetection Human Biosurveillance Research and Development for National Security (2018)
- Global Health Security Index (2019)
- Achieving Health Security and Threat Reduction through Sharing Sequence Data (14-May-2019)
- A DETERRENCE BY DENIAL STRATEGY FOR ADDRESSING BIOLOGICAL WEAPONS (23-Sept-2021)
- The New Normal: What is the UK Biosecurity State? (30-Jul-2020)
- Nick Bostrum: UK Biosecurity – Integrated Review: Call for Evidence (1-Sept-2020)
- Beyond the Pandemic: Prepare and plan a biosecure future – Luke Kemp, Centre for Existential Risk (Oct 2021)
MILITARY BIOTECH
- Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy (16-Dec-2021)
- US Army Creates Single Vaccine Against All COVID & SARS Variants, Researchers Say (21-Dec-2021)
- The Race for a COVID-19 Vaccine w/ US Army Scientist Kayvon Modjarrad, MD, PhD (10-Jun-2020)
- Nanoparticle-Based Vaccines Against Respiratory Viruses (24-Jan-2019)
- Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprrotein to Avoid Neutralization Escape (19-Jan-2018)
- A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein (Mar-2020)
- A SARS-CoV-2 Vaccine Candidate Would Likely Match All Currently Circulating Strains (27-Apr-2020)
- Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial (May-2020)
- Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks (9-Jul-2020)
- A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants (22-Sept-2020)
- SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity (27-Mar-2021)
- A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic (8-Mar-2021)
- A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells (28-Apr-2021)
- Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform (3-Jun-2021)
- The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response (7-Jun-2021)
- Serological and RT-PCR Surveillance for COVID-19 in an Asymptomatic US Army Trainee Population (29-Jul-2021)
- Prioritizing interventions for preventing COVID-19 outbreaks in military basic training (10-Dec-2021)
- SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity (4-Dec-2021)
- Platform for antigen presentation and vaccine development (17-Jul-2006)
- Doxorubicin loaded ferritin nanoparticles for ferroptosis enhanced targeted killing of cancer cells (14-Jun-2019)
- Light chain human ferritin (17-Sept-2013)
- Fluorescent ferritin nanoparticles and application to the aptamer sensor (1-Aug-2011)
- Remote control of gene expression/magnetogenetics
- Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity (28-Dec-2020)
- Covid-19 ferritin nanoparticle vaccine, illustration
- Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine (Patent)
- Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates (25-Mar-2021)
- Prioritizing interventions for preventing COVID-19 outbreaks in military basic training
- Preventing the next pandemic: Inside the quest to find a universal vaccine against all coronaviruses (24-Nov-2021)
- ‘Another one was coming’: Army scientists working on vaccine had long feared emergence of new coronaviruses (14-May-2020)
- A government official tried to share optimism about vaccines — but he hinted at a dark possible future (9-Jul-2020)
MILITARY RESEARCH
- Phase 1 clinical trial of WRAIR-developed COVID-19 vaccine begins (5-Apr-2021)
- A next-gen Army COVID vaccine you’ve never heard of has just begun human trials (8-Apr-2021)
- Army to highlight future pandemic preparedness efforts at AUSA (6-Oct-2021)
- Dr Kayvon Modjarrad on Global Health at Vanderbilt forum (21-Sept-2017)
- Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy (16-Dec-2021)
- 10% of people on a flight from Miami to Tel Aviv tested positive for COVID-19, despite rules mandating a negative test to fly (21-Dec-2021)
- Next-Generation Sequencing for Biodefense: Biothreat Detection, Forensics, and the Clinic (1-Mar-2021)
- A Department of Defense Laboratory Consortium Approach to Next Generation Sequencing and Bioinformatics Training for Infectious Disease Surveillance in Kenya (25-Dec-2020)
- How Cooperative Engagement Programs Strengthen Sequencing Capabilities for Biosurveillance and Outbreak Response (1-Mar-2021)
- Towards a genomics-informed, real-time, global pathogen surveillance system (13-Nov-2017)
- Navy Tests Next Generation Sequencing to Gather DNA Information (6-Aug-2013)
- Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial (6-May-2020)
- Combat Infectious Diseases Research Org
- National Guard Covid Response
- Oxford University: Anti-cancer drug derived from fungus shows promise in clinical trials (8-Oct-2021)
- UNC: 3D Printed Vaccine Patch Offers Vaccination Without a Shot (24-Sept-2021)
NARRATIVES
GLOBAL PICTURE
GOVERNANCE
- Trump administration (start of pandemic to exit January 2021) incompetent and luddite about Coronavirus messaging (same as Boris Johnson in the UK) – preferring to ignore the early spread, wasting months in stubborn denialism and let Dr Fauci move front and centre
- Operation Warp Speed (military) brought in by Trump midway through 2020 to husband the developing vaccines to market
- Organisation of lockdowns, quarantine, public health measures – testing, prophylaxis, vaccine deployment, by-laws – passed to State administrations, coopted by the red-v-blue internecine in the US
- Genuine divergence of approach between “Establishment” and maverick Trump administration – the former quickly arranged around Dr Fauci and the Democratic Party, proliferating a “Trust The Science” orthodox hegemony as the antidote to Trump/GOP chaos (wilful stupidity)
- Trillions of dollars transferred from taxpayer revenue to big corporate interests (CARES Act and equivalents in the UK/EU) especially pharma, tech, transport and the military industrial confederacy
- Manipulated vaccine data, demonisation of the unvaccinated, fearporn focus of media reportage, authoritarian solutions and data obfuscation in official bulletins from Fauci and – once in office – the Biden administration: historically familiar tropes deployed through 21st-century media and tech platform propaganda
- Under threat of antitrust, Silicon Valley forced into the censorship game – working on behalf of the plutocracy and its official agenda – to silence opposition (dissent) at unprecedented scale including aggressive censorship of anything and anyone diverging from loyal orthodoxy (in the name of duty to best public health outcomes)
- In typical manufacturing consent fashion, a controlled bullshit spigot of numbers and data and “expert” analysis published 24/7 across the US, UK, Europe and elsewhere about near-perfect efficacy of vaccines, the danger to unvaccinated, the uselessness of prophylaxis, the impossibility of treatment etc
- Despite the high vaccine efficacy headlined at home, no vaccine program comes together to cover the poorer nations – and thus no possibility of stamping out Coronavirus or preventing new variants from arising
- Corporate America has emerged wealthier since pandemic start – consolidating, receiving huge taxpayer funds, dropping the economic hit on the middle and working class (e.g. for lockdowns)
- America’s election (November 2020) removes Trump as a loose cannon as Biden wins Presidency, Democratic Party takes control of the Senate and the House of Reps
- Progressive opposition is castrated (captured) by corporate politicians while the Democratic Party ensures no disruption to maximising revenue/profit (upward wealth transfer) while hobbling social programs and dispersing leftover energy from 2020 protests like Black Lives Matter
FUNDING
- Coronavirus vaccine development – once SARS-CoV2 pandemic was underway – received acceleration funding from two US federal agencies—the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA)
- Separate channels of American government-military funding (DARPA) and government-civilian science grants (NIH and Fauci) worked out an evolving gain-of-function research collaboration with the Chinese Communist Party and Wuhan Institute of Virology – coordinated by Gates/Wellcome once Trump administration reestablished American support
- Scientific/academic research and all corporate media/mainstream politics is funded (captured) by the interests of the Gates Foundation and the Wellcome Trust – between them controlling over 60% of funding worldwide
- US Govt controls Pfizer/BioNtech and Moderna patents through Bayh-Doyle Act because – as with over 90% of drug/interventions on the market – the NIH managed the funding of vaccine platform/tech development including the all-important underlying mRNA technology
- US public health authorities (NIH, BARDA, CDC, FDA) are directed by the Gates Foundation
- UK public health authorities (UKHSA, NICE) are directed by the Wellcome Trust
Pfizer/Moderna (i.e. NIH patent holder) is not sharing vaccine recipe to protect the mRNA platform – separate to the whole Coronavirus pandemic. The mRNA platform has potential for revenue streams that dwarf the billions in profit from SARS-CoV-2 e.g. it has myriad uses as a cancer delivery drug, which is perhaps the biggest prize in medical science – a bonanza of incalculable trillions that could roll on and on for decades. This is why the patent isn’t going to be shared. It won’t be shared until the technology can be shared in a way that doesn’t open access beyond targeted Coronavirus usage. The vaccine corporations will doubtless be working on a nerfed version. If they find it, there will be a fanfare of “patent sharing”. Gates Foundation (USA) and Wellcome Trust (UK) are key players in this global strategy.
CENSORSHIP
- Dr Fauci and military Operation Warp Speed work aggressively to keep messaging consistent (and away from scrutiny of Wuhan Institute of Virology). China is also keen to suppress investigation
- Big Tech is weaponised to censor dissent from any source, scientist or layperson i.e. YouTube, Twitter, Facebook, Google: hand in glove with government mandate
- Expect censorship to continue, subjects diversifying according to government priority as directed by vaccine makers and political expedience
- Big tech antitrust regulation is a stick politicians use to beat Silicon Valley corporate platforms into submission – taxation a clear and present penalty, to force corporations and billionaire CEOs into line
- Expect transgressions that risk profit or power to be punished with increasing force
- Too much money is flowing and too many powerful people have staked their future on the current strategy of creating a multi-trillion dollar Coronavirus -> Vaccine Biotech Political-Industrial scale-up
- Expect genuine alternate preventions (prophylaxis) and treatments to be aggressively marginalised – exponents vilified – disloyalty rather than right-or-wrong the litmus for inclusion in the public square
- Will there be a paradigm shift?
- Look for testing standards that never coalesce and vaccine approval bias that continue to choose profit over lives
- Does the American FDA allow no-profit AstraZeneca ad-vector vaccine into the US market?
- Expect shifting standards in the media shilling for vaccine and vaccine mandates as efficacy data becomes less falsifiable real-world but maximum profit will inform the narrative
- Messaging will quietly shift if vaccines don’t protect enough i.e. propaganda about extra/regular shots, excuses like “the virus mutated”, “blame the unvaccinated”, “hospital burden”, “efficacy wanes” etc
HEALTH AUTHORITY ORDERS
- Australia – New South Wales – Public Health COVID-19 General Order No 2 (2021-2022) + In Force Amendments (12-Jan-2022)
- Australia – New South Wales – Air Transportation Quarantine Order No 4 (2021-2022) + Amendments (12-Jan-2022)
MEDIA BULLSHIT SPIGOT
- Texas children and children’s hospitals are under siege from two viruses: RSV and COVID-19 (12-Aug-2021)
- Texas Tribune makes major COVID-19 error, publishes weaselly correction (13-Aug-2021)
CORONAVIRUS AT WARPSPEED
- Gain-of-function banned in the US
- Moved to Wuhan, China
- Funded by NIH through Ecohealth (Fauci, Dahsak)
- Wuhan lab used animals for research, including bats
- In 2019, a novel coronavirus escaped from the Institute of Virology
- Evidence of infection at World Military Games 2019
- Major outbreak spread from Wuhan late 2019/early 2020
- CCP couldn’t contain it, despite authoritarian lockdown and early suppression
- SARS-CoV-2 novel coronavirus went worldwide
- Covid-19, the disease created by SARS-CoV-2, declared pandemic
NARRATIVE NOTES
- Early 2020. World Health Organisation declares pandemic. Coronavirus goes global. China shares viral genetic codes (3 day delay). Chinese scientists from the Wuhan lab register early Covid-19 vaccine patents along with Moderna and BioNtech-Pfizer.
- Wet market narrative is inserted. China, WHO, CDC, US Govt and others are in lockstep with an official consensus: accidental coronavirus mutation from animals to humans went pandemic, no lab leak, lockdowns across the world to minimize infections, mass media husband public demand for vaccine ASAP.
- There’s no evidence Coronavirus was being weaponized by China or that its escape was planned. There’s plenty of evidence Wuhan lab is the source, gain-of-function conditions bred the initial pandemic variant and China was working directly with America through Ecohealth, a front for the NIH/DARPA, run by Dr Fauci and his delegate Dr Dahsak.
- Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public.
- The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. What’s more, trial data is limited by short time period reporting that don’t take into account increase or decrease in efficacy outside the short window of back to back testing.
PUBLIC IMPACT
- Reported Deaths from Covid by Age in the United States
- “United Polarity” Aubrey Marcus and Mattias Desmet: Connecting beyond our thoughts and beliefs (9-Dec-2021)
- COVID-19 and the Political Economy of Mass Hysteria (3-Feb-2021)
- VIDEO: Why People WILLINGLY Give Up Their Freedoms W/ Prof Mattias Desmet | YouTube Video | Aubrey Marcus Podcast (6-Dec-2021)
- How The Koch Network Hijacked The War On COVID (22-Dec-2021)
GAIN OF FUNCTION
- Gain-of-function research has a long controversial history and by the time Obama administration signed off on American labs not doing it, EU had also banned it. China has no such restrictions on risky leading edge medical research.
- CCP and Chinese military scientists were brought on board. SARS had hit China. The CCP had been working at research already and was keen to benefit from importing state-of-the-art tech + science.
- Wuhan Institute of Virology ramped up world leading gain-of-function research and other key internationally sanctioned biological virus science.
mRNA PLATFORM
- Development of mRNA technology has been in progress for over 20 years, primarily with a view to opening a new deliver mechanism and drug potential for cancer treatments
- Decades of money has poured in from many governments but majority from the US Pentagon (DARPA), Gates Foundation (US) and Wellcome Trust (UK) – by far the dominant capital power-centres in the biotech biomed sector
- Various science hurdles had to be overcome; and NIH funding decisions drove the research in the US
- UK and Franco-German (EU) government funding equivalents, both importing (licensing) the technology once the patented messenger RNA delivered in lipid shell mechanism was OK’d by US
- Govt as NIH licensed mRNA tech to careful selections like BioNtech, Moderna, Cellscript and other “Western” biotech corporations
- While mRNA was originally found to be viable for in vivo gene transfer in the early 1990’s, the development of mRNA vaccines was initiated much later due to the inherent instability of mRNA compared to DNA
- Coronavirus Vaccine – and underlying platform access – is monopolised by US/UK governments who hold power over Coronavirus treatment regulation (patents) and mass mandate law (policing)
- Governments ostensibly regulate on behalf of pharmaceutical corporations (profit engines) and health authorities (funding distributors) but ultimately the industry is coordinated by Gates Foundation/Wellcome Trust (source of over 60% global money in all medical and biotech)
- Biotech and biomedical response to the SARS-CoV-2 virus is part opportunist, part long-term plan forced to execute slightly early: a multi-trillion dollar scale-up (wealth transfer) and consolidation of new centralised power (neoliberal hegemony)
REGULATORY CAPTURE
- Future jobs of FDA’s haematology-oncology reviewers (27-Sept-2016)
- Scott Gottlieb Joins Pfizer Board Weeks After Departing from FDA (28-Jun-2019)
- The Regulatory Capture Of The FDA (12-Jun-2021)
- Freedom of Information Law Suit against CDC Refusal to Provide Public Data (28-Dec-2021)
EMERGENCY USE AUTHORISATIONS
- FDA emergency approval requires there to be no viable available treatment methods. This makes it essential to vaccine profit to squash ANY existing protocol (e.g. ivermectin + steroid + fluvoxamine blend) gaining official recognition
- Censorship targets “treatment” and “prophylaxis” lines of public discussion consistent with Big Pharma/Big Tech/CDC strategy for maximum vaccine revenue
- Alternative prophylaxis and treatment protocols for SARS-CoV2 and Covid-19 – like commonplace diet regimens, Vitamin D, weight control, antivirals (ivermectin), monoclonal antibodies – are pushed out of the mainstream and publicly discredited, despite growing evidence and clinician support
- There’s no profit from off-patent generics
- Allowing zero profit medication to play a significant role as a Covid-19 treatment – including, in the US, the AstraZeneca vaccine – would reduce mRNA vaccine profits by multi-billions of dollars
WARPSPEED TRIALS
- Trials of vaccines begin early/mid 2020 and stages become truncated to get the vaccines into play at unprecedented timescale
- By Stage III (late 2020) the mRNA vaccine trial studies have been designed from the outset to win FDA authorization and return very high efficacy
- Authorization of high-profile high-profit vaccines is pushed through fast, to get to market and lock in the billions in sales
- “Emergency authorization terms require there to be no extant alternative – no other COVID-19 treatment drugs.”
- Emergency Use Authorization of Medical Products and Related Authorities (2017): “For FDA to issue an EUA, there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition” i.e. hydroxychloroquine and ivermectin must stay unapproved and discredited
- Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial (2-Nov-2021)
- PRESS RELEASES
- Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows:
- relative risk reduction, 95.1%; 95% CI, 90.0% to 97.6%; p = 0.016;
- absolute risk reduction, 0.7%; 95% CI, 0.59% to 0.83%; p < 0.000
- For the Moderna vaccine mRNA-1273, the appraisal shows:
- relative risk reduction, 94.1%; 95% CI, 89.1% to 96.8%; p = 0.004
- absolute risk reduction, 1.1%; 95% CI, 0.97% to 1.32%; p = 0.000ish
- Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures
- Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy
- Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows:
BEATING THE PANDEMIC
BASICS
- Vaccinated people catch Covid and spread it
- Vaccine mandate targeting frontline employees does NOT protect workplaces
- Antigen (lateral flow) tests cost pennies to manufacture and can be distributed free to everyone, everywhere
- Antigen tests specifically answer the question “am I infectious?” in 10 minutes
- Home testing lets people isolate if the antigen result is “infectious” before they spread by close contact with anyone else
- Knowing if someone is infectious WILL protect workplaces – and at scale it’ll protect society at large
“The endless obsession with vaccination – whether or not you’re the type who gives a c**p about Big Pharma grift, regulatory capture, faith in govt – is hurting public health. It’s hurting treatment. It’s hurting community trust. It’s hurting testing infrastructure. It’s hurting product competition. It’s poisoning quality of life.”
The best public health approach to SARS-CoV-2 is a simple TEST-TREAT-PREVENT protocol:
THREE POINT RESPONSE
- Universal antigen and community wastewater testing
- Proactive prophylaxis and unshackled doctor-patient treatment
- Vaccination based on UP-TO-DATE testing of neutralizing antibody titers i.e. using an individual’s current immunological response to both prior vaccine/s AND prior infection/s
- No need for lockdowns. No mandates. No one size fits all rules. No apartheid. No travel bans. No unnecessary quarantines. No interfering with doctor patient relationships. No school closure. No masked children. No mass job terminations. No persecution or villifying others
Why is it so hard to bring in data-driven protocols?
Why are the simple necessary measures still being debated? Is it honest?
TEST-TREAT-PREVENT protocols allow corporations make their profit but without compromising public health. It should be a no brainer.
TIMELINE
2003-2019
- The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States (24-Feb-2003)
- Intradermal influenza vaccination–can less be more? (3-Dec-2004)
- Suppression of RNA Recognition by Toll-like Receptors: Nucleoside Modification and RNA Origin (6-Aug-2005)
- Penn Study Finds a New Role for RNA in Human Immune Response (23-Aug-2005)
- Platform for antigen presentation and vaccine development (17-Jul-2006)
- Immunity and immunological memory following smallpox vaccination (2-Nov-2006)
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness (1-Oct-2008)
- Estimating Influenza-Associated Deaths in the United States (12-Dec-2008)
- India says no to HIV drug patents (3-Sept-2009)
- Incorporation of Pseudouridine into mRNA Enhances Translation by Diminishing PKR Activation (10-May-2010)
- India fears generic drugs for poor are endangered by proposed EU trade deal (6-Jul-2010)
- Broad-Spectrum Antiviral Therapeutics (27-Jul-2011)
- Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008 (15-May-2012)
- Large, Single Dose, Oral Vitamin D Supplementation in Adult Populations: A Systematic Review (20-Apr-2014)
- Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity (26-Dec-2015)
- Graphene and the immune system: Challenges and potentiality (21-Jan-2016)
- Pre-Fusion Structure of a Human Coronavirus Spike Protein (2-March-2016)
- Gain-of-Function Research: Ethical Analysis (8-Aug-2016)
- Immunological effects of graphene family nanomaterials (22-Sept-2016)
- Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms (13-Oct-2016)
- Sick pay and sickness benefit schemes in the European Union (17-Oct-2016)
- Moderna Therapeutics: Moderna’s Mysterious Medicines (14-Dec-2016)
- Graphene toxicity as a double-edged sword of risks and exploitable opportunities: a critical analysis of the most recent trends and developments (25-Jan-2017)
- Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 (17-May-2017)
- Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparednes (19-Aug-2017)
- Why Did the CDC Silence the Million Dollar Harvard Project Charged With Upgrading Our Vaccine Safety Surveillance System? (24-Oct-2017)
- NIH Lifts Funding Pause on Gain-of-Function Research (19-Dec-2017)
- β-d-N4-Hydroxycytidine (Molnupiravir) Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome (21-Jan-2018)
- Pricing of monoclonal antibody therapies: higher if used for cancer? (24-Feb-2018)
- Seasonal Incidence of Symptomatic Influenza in the United States (15-May-2018)
- US v Pfizer Inc: Anti-Kickback Criminal Court Settlement | Pfizer Corporate Integrity Agreement with Dept of HHS (20-May-2018)
- Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome (20-May-2018)
- Heterogeneity and longevity of antibody memory to viruses and vaccines (10-Aug-2018)
- A human enzyme can biodegrade graphene (23-Aug-2018)
- “Just Carbon”: Ideas About Graphene Risks by Graphene Researchers and Innovation Advisors (22-Oct-2018)
- Environmental Biodetection Human Biosurveillance Research and Development for National Security (2018)
- Global Health Security Index (2019)
- Nanoparticle-Based Vaccines Against Respiratory Viruses (24-Jan-2019)
- Achieving Health Security and Threat Reduction through Sharing Sequence Data (14-May-2019)
- Simultaneous delivery of DNA vaccine and hydrophobic adjuvant using reducible polyethylenimine-functionalized graphene oxide for activation of dendritic cells (31-May-2019)
- Scott Gottlieb Joins Pfizer Board Weeks After Departing from FDA (28-Jun-2019)
- Understanding the Emergence of Bat Coronavirus (14-Jul-2019)
- Event 201 at Center for Health Security (18-Oct-2019)
- Differential Expression of Neuroinflammatory mRNAs in the Rat Sciatic Nerve Following Chronic Constriction Injury (24-Oct-2019)
- How CDC Estimates the Burden of Seasonal Influenza in the U.S. (22-Nov-2019)
- How Prepared Are We For The Next Pandemic? Not Very, Experts Show (12-Dec-2019)
- Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus) (2019/2020)
2020
January 2020
- Moderna’s Work on COVID-19 Vaccine (11-Jan-2020)
February 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat origin (2-Feb-2020)
- Study claiming new coronavirus can be transmitted by people without symptoms was flawed (3-Feb-2020)
- Top disease official: Risk of coronavirus in USA is ‘minuscule’; skip mask and wash hands (17-Feb-2020)
- Blind Spot – How the COVID-19 Outbreak Shows the Limits of Pharma’s Monopoly Model (19-Feb-2020)
- Statement in support of the scientists and medical professionals of China against COVID-19 (19-Feb-2020)
- Metro UK: Anyone ordered to self-isolate is entitled to paid sick leave (26-Feb-2020)
- Bustle: What Financial Support You Can Get If You Can’t Work Due To Coronavirus (27-Feb-2020)
- CNN: Sick Employees Should Stay Home to Fight Coronavirus – But Many Don’t Have Sick Leave (29-Feb-2020)
March 2020
- Buzzfeed: Here’s What You Need To Know About Air Purifiers And Coronavirus (3-Mar-2020)
- Unreasonable Pricing in a “Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” (5-March-2020)
- Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease (8-Mar-2020)
- Are both supplemental magnesium and vitamin K2 combined important for vitamin D levels? (10-Mar-2020)
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study (11-Mar-2020)
- Senate GOP Blocks Emergency Paid Sick Leave Bill From Moving Forward (13-Mar-2020)
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation (13-Mar-2020)
- Three Problem Areas in Section 202 of the Bayh-Dole Act (14-Mar-2020)
- This is how Europe is helping companies and workers as the coronavirus crisis deepens (16-Mar-2020)
- SARS-CoV-2 and COVID-19: The Most Important Research Questions (16-Mar-2020)
- EIDD-2801 is the isopropylester prodrug of [N4-hydroxycytidine – Merck Sponsored as Molnupiravir (16-Mar-2020)
- Pfizer BioNTech Partnership Agreement (17-March-2020)
- Coronavirus: Employment rights and sick pay – United Kingdom (17-Mar-2020)
- How UK sick pay compares with Europe as coronavirus triggers calls for SSP rise (18-Mar-2020)
- Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures (19-Mar-2020)
- Sweden: Government Temporarily Amends Sick Leave Rules During Coronavirus Outbreak (20-Mar-2020)
- KEI Letter to Nancy Pelosi Regarding Use of “Other Transaction Authority” (23-Mar-2020)
- Gilead Sciences Coronavirus Treatment gets “Rare Disease” Status (24-Mar-2020)
- WHO Director-General’s opening remarks at the media briefing on COVID-19 (28-Mar-2020)
- Buying Know-How to Scale Vaccine Manufacturing (30-Mar-2020)
April 2020
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (Apr-2020)
- How Big Pharma Is Getting Ready To Blackmail Americans (3-Apr-2020)
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro (3-Apr-2020)
- Minimum costs to manufacture new treatments for COVID-19 (6-Apr-2020)
- Prefusion Coronavirus Spike Proteins and Their Use (8-Apr-2020)
- Physical interventions to interrupt or reduce the spread of respiratory viruses: masks, eyewear, distancing (7-Apr-2020)
- European Union Draft Resolution on COVID-19 for WHA73 (15-April-2020)
- Moderna Announces Award from U.S. Govt Agency BARDA $483 Million for mRNA Vaccine (16-Apr-2020)
- Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus) (16-Apr-2020)
- European Union urges the World Health Assembly to Pursue a Voluntary Pool for Covid-19 (16-April-2020)
- NIH announces strategy for developing COVID-19 drugs, vaccines (17-April-2020)
- “Did COVID-19 come from a lab in Wuhan?” (17-Apr-2020)
- Heads of WTO, WHO cite importance of open trade in ensuring flow of vital medical supplies (20-Apr-2020)
- “Von der Leyen announces Global Response and calls for united world front against coronavirus.” (20 April 2020)
- ScienceDirect: How can airborne transmission of COVID-19 indoors be minimised? (22-Apr-2020)
- New York clinical trial quietly tests heartburn remedy against coronavirus (26-Apr-2020)
- A SARS-CoV-2 Vaccine Candidate Would Likely Match All Currently Circulating Strains (27-Apr-2020)
- Powered air-purifying respirators (PAPRs) help doctors and nurses treat coronavirus patients – Multiple Studies (Apr-2020)
May 2020
- Covid-19: A Vaccine For Us All? (May-2020)
- An emerging antiviral takes aim at COVID-19 (5-May-2020)
- French athlete ‘caught coronavirus’ in October 2019 (6-May-2020)
- Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2 (6-May-2020)
- Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug (13-May-2020)
- ‘Another one was coming’: Army scientists working on vaccine had long feared emergence of new coronaviruses (14-May-2020)
- CNN: France’s President Macron says human health “cannot be bought and sold” (18-May-2020)
- Moderna Announces Pricing of Public Offering of Shares of Common Stock (18-May-2020)
- Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus (18-May-2020)
- Moderna’s chief financial officer and chief medical officer sold nearly $30 million of shares combined on May 18 and May 19 2020 (19-May-2020)
- Moderna unveiled encouraging coronavirus vaccine results. Then top execs dumped nearly $30 million of stock (22-May-2020)
- Interesting Engineering: Latest Updates on the Coronavirus Disease (28-May-2020)
- Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 (28-May-2020)
- Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines (May to July 2020)
June 2020
- Moderna’s coronavirus vaccine announcement set off a frenzy on Wall Street. Now some are calling for an investigation (1-Jun-2020)
- Merck Joins The COVID Drug Race With EIDD-2801 – And A Chemistry Lesson From Hell (1-Jun-2020)
- ‘I would not recommend this.’ A scientist’s hydroxychloroquine trial—and his advice to Trump (4-Jun-2020)
- What Scientists Know About the COVID-19 Virus (6-Jun-2020)
- Portal to Alternative Futures in the Making (8-Jun-2020)
- The Race for a COVID-19 Vaccine w/ US Army Scientist Kayvon Modjarrad, MD, PhD (10-Jun-2020)
- The Perfect Vaccine (11-Jun-2020)
- Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen (12-Jun-2020)
- Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review (14-Jul-2020)
- Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study (22-Jul-2020)
- Coronavirus NIH Vaccine 2015-2020 – US Government Funded mRNA Patents (25-Jun-2020)
- Surveillance testing of SARS-CoV-2 (25-Jun-2020)
- The NIH claims joint ownership of Moderna’s coronavirus vaccine (25-Jun-2020)
- Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance (27-Jun-2020)
- BUSTED: NIH Owns Financial Stake In Gates-Funded Coronavirus Vaccine (30-June-2020)
- Did the Military World Games Spread COVID-19? (30-Jun-2020)
July 2020
- FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems (1-Jul-2020)
- ‘A Scandal’: Contracts Show Trump Giving Big Pharma Free Rein to Price Gouge Taxpayer-Funded Coronavirus Drugs (2-Jul-2020)
- Aura Air filter tackles COVID-19 virus in vehicles (2-Jul-2020)
- Pandemic-Proofing Travel (3-Jul-2020)
- The critical role of paid sick leave in the COVID-19 health and labour market crisis (8-Jul-2020)
- Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks (9-Jul-2020)
- Newly designed air filter can ‘catch and kill’ COVID-19 (10-Jul-2020)
- Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 (13-Jul-2020)
- Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic (15-Jul-2020)
- COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial (20-Jul-2020)
- United Airlines – How the air you breathe onboard stays clean (20-Jul-2020)
- Coronavirus: B cells and T cells explained (20-Jul-2020)
- Impact of National Containment Measures on Decelerating the Increase in Daily New Cases of COVID-19 in 54 Countries and 4 Epicenters of the Pandemic: Comparative Observational Study (22-Jul-2020)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (28-Jul-2020)
- The Ultimate Geopolitical Game — Distributing a Coronavirus Vaccine (29-Jul-2020)
- The Atlantic: We Need To Talk About Ventilation (30-Jul-2020)
August 2020
- Form 8-K Oragenics Inc: Current report (Aug-2020)
- The effects of vitamin D on acute viral respiratory infections: A rapid review (3-Aug-2020)
- Federal Court Strikes Down Labor Department’s Limitations On Paid Sick And Extended Leave Benefits Under FFCRA (6-Aug-2020)
- Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection (7-Aug-2020)
- Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events (7-Aug-2020)
- Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? (13-Aug-2020)
- Australian High Court rules against increasing paid sick leave for shift workers (14-Aug-2020)
- The great gamble of COVID-19 vaccine development (17-Aug-2020)
- The first 10 000 COVID-19 papers in perspective: are we publishing what we should be publishing? (20-Aug-2020)
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review (25-Aug-2020)
- Forecasting for COVID-19 has failed (25-Aug-2020)
September 2020
- Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3-Sept-2020)
- A concise route to MK-4482 (EIDD-2801) from cytidine (3-Sept-2020)
- Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine (4-Sept-2020)
- Exponential-growth prediction bias and compliance with safety measures related to COVID-19 (16-Sept-2020)
- SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels (17-Sept-2020)
- A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants (22-Sept-2020)
- Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study (23-Sept-2020)
- Regeneron’s REGN-CoV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients (29-Sept-2020)
October 2020
- CDC: Past Seasons Estimated Influenza Disease Burden 2011-2019 (1-Oct-2020)
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS- CoV-2 (1-Oct-2020)
- Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis (2-Oct-2020)
- Vaccines and Related Biological Products Advisory Committee October 2, 2020 Meeting Announcement (2-Oct-2020)
- Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity (4-Oct-2020)
- GREAT BARRINGTON DECLARATION (4-Oct-2020)
- Using viral load and epidemic dynamics to optimize pooled testing in resource constrained settings (6-Oct-2020)
- Global perspective of COVID-19 epidemiology for a full-cycle pandemic (7-Oct-2020)
- Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 (7-Oct-2020)
- A High-Yielding Synthesis of EIDD-2801 from Uridine (7-Oct-2020)
- Covid-19: Modelling the pandemic: Imperial College early case scenarios (7-Oct-2020)
- COVID19: A Strange Worldwide Pandemic (16-Oct-2020)
- Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (17–Oct-2020)
- Save the Date – Government Funding of COVID-19 Vaccines and Other Medical Technologies (20-Oct-2020)
- “Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases” (22-Oct-2020)
- The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries (22-Oct-2020)
- A Federal Coronavirus Vaccine Contract Released At Last, But Redactions Obscure Terms (23-Oct-2020)
- Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab (26-Oct-2020)
- Analysis of Covid-19 Data for Eight European Countries and the United Kingdom Using a Simplified SIR Model (29-Oct-2020)
- Independent Scientific Pandemic Insights Group on Behaviours (SPI-B) (Oct-2020)
- A Comparative Study on the Strategies Adopted by the United Kingdom, India, China, Italy, and Saudi Arabia to Contain the Spread of the COVID-19 Pandemic (30-Oct-2020)
November 2020
- The hidden public health hazard of rapid Covid-19 tests (5-Nov-2020)
- Pfizer Vaccine’s Funding Came From Berlin, Not Washington (9-Nov-2020)
- The challenges of data usage for the United States’ COVID-19 response (9-Nov-2020)
- Analysis: Pfizer Vaccine Relies on U.S. Government-Developed Spike Protein Technology (10-Nov-2020)
- COVID-19 destroying air filter tested in opticians enters the market (10-Nov-2020)
- SARS-COV-2 Virus: infection mechanism and life cycle – 2-minute video (10-Nov-2021)
- The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race (10-Nov-2020)
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (12-Nov-2020)
- Diversity of Contract Terms Illustrates Need for Transparency of Covid-19 Contracts (13-Nov-2020)
- Government-Funded Scientists Laid Groundwork For Billion-Dollar Vaccines (19-Nov-2020)
- Evaluating COVID Risk on Planes, Trains and Automobiles (19-Nov-2020)
- Initial data shows arthritis drug is effective in treating sickest Covid-19 patients (19-Nov-2020)
- Landmark Danish (DANMASK-19) Study: No Significant Effect for Facemask Wearers (19-Nov-2020)
- Physical interventions to interrupt or reduce the spread of respiratory viruses (20-Nov-2020)
- Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (21-Nov-2020
- Vaccine Contracts Shrouded in Secrecy Despite Massive Public Funding (23-Nov-2020)
- Comparing COVID Vaccines: Pfizer vs Moderna vs AstraZeneca/Oxford (23-Nov-2020)
- Covid-19: controversial trial may actually show that masks protect the wearer (24-Nov-2020)
- “…nothing wrong with profit, guys. Despite development being publicly funded…”
- Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate (27-Nov-2020)
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (28-Nov-2020)
- The COVID-19 insidious trick: Subjective perception of numbers (29-Nov-2020)
- Foundational mRNA Patents are Subject to the Bayh-Dole Act Provisions (30-Nov-2020)
- How COVID vaccines are being divvied up around the world (30-Nov-2020)
December 2020
- Precision shielding for COVID-19: metrics of assessment and feasibility of deployment (1-Dec-2020)
- Moderna’s Coronavirus Vaccine Largely Funded by $1B Taxpayer Dollars (3-Dec-2020)
- SARS-CoV-2 indoor contamination: considerations on anti-COVID-19 management of ventilation systems, and finishing materials in healthcare facilities (4-Dec-2020)
- Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (9-Dec-2020)
- The Pfizer Coronavirus Vaccine Is Near Approval, but U.S. May Have to Wait to Buy More (11-Dec-2020)
- Why an Australian COVID-19 vaccine caused false-positive HIV tests (11-Dec-2020)
- What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? (11-Dec-2020)
- World Faces COVID-19 Vaccine Apartheid (13-Dec-2020)
- Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (14-Dec-2020)
- Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2 (14-Dec-2020)
- NIH funding for vaccine readiness before the COVID-19 pandemic (17-Dec-2020)
- NYT: Covid-19 Vaccines Are Supposed to Be Free – Surprise Bills Could Happen Anyway (17-Dec-2020)
- SPI-B: Possible impact of the COVID-19 vaccination programme on adherence to rules and guidance about personal protective behaviours aimed at preventing spread of the virus (17-Dec-2020)
- PDMJ: Data that disprove the COVID-19 pandemic? (19-Dec-2020)
- A guide to vaccinology: from basic principles to new developments (22-Dec-2020)
- The Use of Digital Tools to Mitigate the COVID-19 Pandemic: Comparative Retrospective Study of Six Countries (23-Dec-2020)
- COVID-19 RNA Based Vaccines and the Risk of Prion Disease (27-Dec-2020)
- FACT SHEET: Federal Coronavirus Paid FMLA, Sick Leave Requirements (28-Dec-2020)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (31-Dec-2020)
2021
January 2021
- Effect of 1% Povidone Iodine Mouthwash/Gargle, Nasal and Eye Drop in COVID-19 patient (1-Jan-2021)
- Genomic evidence for reinfection with SARS-CoV-2: a case study (1-Jan-2021)
- Icon PLC: Covid-19 Pfizer/BioNtech Vaccine Trials (4-Jan-2021)
- Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19 (5-Jan-2021)
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection 6-Jan-2021)
- Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials (13-Jan-2021)
- Fact Sheet: Activity at the Wuhan Institute of Virology (15-Jan-2021)
- mRNA and Viral Vector Coronavirus Vaccine Types (15-Jan-2021)
- Pfizer/BioNTech COMIRNATY®, COVID-19 vaccine (18-Jan-2021)
- Evolution of antibody immunity to SARS-CoV-2 (18-Jan-2021)
- The immune system mounts a lasting defense after recovery from COVID-19 (18-Jan-2021)
- The impact of the 2019 World Military Games on the COVID-19 pandemic (19-Jan-2021)
- Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents (20-Jan-2021)
- Principles and guidelines for reporting on Covid-19 vaccines (22-Jan-2021)
- Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 (25-Jan-2021)
- Nanoparticle Technology Holds Promise for Protecting Against Many Coronavirus Strains at Once (26-Jan-2021)
- South Africa Allows Use of Parasite Drug in Covid Patients (27-Jan-2021)
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms – Fluvoxamine, Monoclonal Antibodies and Others (27-Jan-2021)
- Mask mandates in light of DANMASK-19 (29-Jan-2021)
- Draft of EU Export Restriction For COVID-19 Vaccines (29-Jan-2021)
- Top mRNA Pharmaceutical Companies
February 2021
- “Coronavirus (COVID-19) vaccines for developing countries: An equal shot at recovery” (4-Feb-2021)
- COVID-19 and the Political Economy of Mass Hysteria (3-Feb-2021)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (4-Feb-2021)
- dw.com: Cancer and mRNA Vaccines (5-Feb-2021)
- Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna (11-Feb-2021)
- CureVac: EU vaccine regulator begins review of German-made jab (12-Feb-2021)
- New York Region – SARS-CoV-2 Lineage Emergence Software Modelling (14-Feb-2021)
- Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People (19-Feb-2021)
- KEI Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines (19-Feb-2021)
- Long-Term Studies Of COVID-19 Vaccines Hurt By Placebo Recipients Getting Immunized (19-Feb-2021)
- Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals (22-Feb-2021)
- Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19 (23-Feb-2021)
- Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events (23-Feb-2021)
- Coronavirus: EU and USA Insist on Vaccination Patents (24-Feb-2021)
- BNT162b2 mRNA Covid-19 Vaccine Mass Vaccination (24-Feb-2021)
- Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study (24-Feb-2021)
- Relative Risk Reduction v Absolute Risk Reduction – Reporting Bias in Vaccine Trials (26-Feb-2021)
March 2021
- Verifying immunity – SYNLAB helps people to monitor their immunity status after vaccination against and recovering from SARS-CoV-2 (Mar-2021)
- Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers (Mar-2021)
- Understanding mRNA COVID-19 Vaccines (2019-2021)
- Waiving Intellectual Property Rules on COVID-19 Products (Mar-2021)
- COVID-19 fatality rates in hospitalised patients: systematic review and meta-analysis (2-Mar-2021)
- Groundbreaking new Covid treatment recommended by Bath scientist (4-Mar-2021)
- Moderna Work Against Potential Covid-19 Vaccine (5-Mar-2021)
- RadVac white paper – Coronavirus Vaccine Recipe (7-Mar-2021)
- A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic (8-Mar-2021)
- See How Strategic Air Purifier Placement Reduces COVID Virus Spread Within Music Classrooms (9-Mar-2021)
- Europe blocks move that would massively expand Covid vaccine production capacity. Why? (10-Mar-2021)
- The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection mode (10-Mar-2021)
- H.R.1319 – American Rescue Plan Act of 2021 (11-Mar-2021)
- Which air purification technologies can tackle COVID-19? (12-Mar-2021)
- The next pandemic: Nipah virus? (15-Mar-2021)
- CRISPR-Based Anti-Viral Therapy Could One Day Foil the Flu—and COVID-19 (16-Mar-2021)
- American Rescue Plan Act: Six Month Extension – Key Employment Aspects (16-Mar-2021)
- James Love Proposal to Eliminate Unreasonable Prices (18-Mar 2021)
- German Team Discover AstraZeneca Thrombosis Link (19-Mar-2021)
- Scientist behind COVID-19 mRNA vaccine says her team’s next target is cancer (19-Mar-2021)
- Buying Know-How to Scale Vaccine Manufacturing (20-March-2021)
- Buying Know-How to Scale Vaccine Manufacturing (20-Mar-2021)
- SARS-CoV-2 antibody kinetics eight months from COVID-19 onset (21-Mar-2021)
- SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors (21-Mar-2021)
- NIAID Statement on AstraZeneca Vaccine (23-Mar-2021)
- BIDEN’S INNER CIRCLE MAINTAINS CLOSE TIES TO VACCINE MAKERS, DISCLOSURES REVEAL (24-Mar-2021)
- Academics & Activists Urge NIH to Use Government-Owned Patents to Increase Vaccine Access (24-Mar-2021)
- Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach (25-Mar-2021)
- AZD1222 US Phase III primary analysis confirms safety and efficacy (25-Mar-2021)
- Tocilizumab in hospitalized patients with COVID-19: A meta analysis of randomized controlled trials (26-Mar-2021)
- Effect estimates of COVID-19 non-pharmaceutical interventions are non-robust and highly model-dependen (26-Mar-2021)
- Promising and Complimentary SARS-CoV2 / Covid-19 Treatments to Optimise Outcomes (28-Mar-2021)
- Trashing Dissenters: What the heck happened to John Ioannidis? (29-Mar-2021)
- License to NIH Spike Protein Technology Needed in COVID-19 Vaccines Demonstrates “Available to the Public on Reasonable Terms” Requirement (30-Mar-2021)
- Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? (30-Mar-2021)
- Role of high-dose exposure in transmission hot zones as a driver of SARS-CoV-2 dynamics (31-Mar-2021)
April 2021
- Employee access to sick leave before and during the COVID-19 pandemic (Apr-2021)
- Coronavirus (COVID-19): Press Conference with Michael Mina, 04/01/21 (1-Apr-2021)
- World Health Organisation: Definition of Universal Health Coverage (1-Apr-2021)
- SARS-CoV-2 Vaccine Clinical Trials Using ACTIV-Informed Harmonised Protocols (April 2021)
- mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic
- COVID-19 Therapeutics Prioritised for Testing in Clinical Trials
- $1.3 Billion J&J COVID Vaccine Development Contract Contains Redactions on Public’s Rights (1-Apr-2021)
- Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins (5-April-2021)
- Indoor Ventilation Strategies to Reduce the Spread of COVID-19 at Home (5-Apr-2021)
- Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era (7-Apr-2021)
- The initial infectious dose of SARS-CoV-2 and the severity of the disease: possible impact on the incubation period (10-Apr-2021)
- Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management (11-Apr-2021)
- Open Letter: Former Heads of State and Nobel Laureates Call on Biden To Waive IP Rules for COVID Vaccine (14-Apr-2021)
- Myths and Facts about COVID-19 Vaccines (as updated (15-Apr-2021)
- Oxford-AstraZeneca Covid Vaccine Research Was 97% Publicly Funded (15-Apr-2021)
- Targeting ACE2 – Closing COVID-19’s cellular doorway (16-Apr-2021)
- Evidence for Increased Breakthrough SARS-CoV-2 Variants in BNT162b2 mRNA Vaccinated Individuals (16-Apr-2021)
- Advance Purchase Agreement between Pfizer and the European Union (17-Apr-2021)
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2 (19-Apr-2021)
- COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room (20-Apr-2021)
- Impact of COVID-19 Testing Strategies and Lockdowns on Disease Management Across Europe, South America, and the United States: Analysis Using Skew-Normal Distributions (21-Apr-2021)
- Preliminary Findings mRNA Vaccines in Pregnant Persons (21-Apr-2021)
- The Pandemic Has Shown Pfizer Is Obsessed With Profits—Not Saving Lives (23-April-2021)
- Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut (26-Apr-2021)
- Workers could get 12 weeks of paid leave under Biden’s plan. Here are the details (28-Apr-2021)
- Two weeks’ paid sick leave at Walmart could have prevented 7,500 Covid cases, report finds (28-Apr-2021)
- Can Cuba beat COVID with its homegrown vaccines? (29-Apr-2021)
- Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (29-Apr-2021)
May 2021
- Emergency Use Authorization for Vaccines to Prevent COVID-19 (May-2021)
- Impact mRNA BNT162b2 Vaccine Against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths (5-May-2021)
- Dr Fauci explains why COVID-19 vaccines work much better than natural immunity to protect you from the coronavirus (5-May-2021)
- COVID-19 hospitalisation, death risk rise ‘sharply’ with BMI (5-May-2021)
- Gates Foundation reverses course on COVID-19 vaccine patents (7-May-2021)
- Indian State Will Offer Ivermectin To Entire Adult Population (11-May-2021)
- COVID-19 testing turns to T cells (12-May-2021)
- Pharma 20 Top Spenders on Research and Development in 2020 (13-May-2021)
- Current Strategies of Antiviral Drug Discovery for COVID-19 (13-May-2021)
- Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs (13-May-2021)
- Use of fear to control behaviour in Covid crisis was ‘totalitarian’, admit scientists (14-May-2021)
- The Evolution of Severe Acute Respiratory Syndrome Coronavirus-2 during Pandemic and Adaptation to the Host (15-May-2021)
- Government Money That’s Gone Into Vaccine Development Is Being Privatised by a Handful of Companies (18-May-2021)
- SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors (18-May-2021)
- Had COVID? You’ll probably make antibodies for a lifetime (26-May-2021)
- Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators (29-May-2021)
June 2021
- Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim: Results and Analysis (Jun-2021)
- Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra (1-Jun-2021)
- Why Relative Risk Reduction not Absolute Risk Reduction is Used in Vaccine Efficacy? (2-Jun-2021)
- Urgent Preliminary Report of Yellow Card Data (9-Jun-2021)
- CDC.GOV: Health Insurance Coverage in the United States (11-Jun-2021)
- Unvaccinated Adults Are More Likely to Be Uninsured, Study Finds (11-Jun-2021)
- KFF COVID-19 Vaccine Monitor: Profile Of The Unvaccinated (11-Jun-2021)
- The Regulatory Capture Of The FDA (12-Jun-2021)
- COVID-19 Pre-Symptomatic Transmission Is Very Real (12-Jun-2021)
- WHO Sued for Lying About Ivermectin and Killing Indians (13-Jun-2021)
- DARPA FUNDING BIG PHARMA. VACCINES NATIONALISM PROFIT (14-Jun-2021)
- Jon Stewart on Stephen Colbert Vented the Wuhan Lab Leak Explanation for Pandemic Origin (14-Jun-2021)
- Dr. Tess Lawrie: COVID vaccines unsafe for human use (14-Jun-2021)
- Latest SWPRS COVID-19 Vaccine Adverse Events (16-Jun-2021)
- Coronavirus: Germany’s CureVac vaccine only 47% effective (16-Jun-2021)
- UK-based Meta Analysis Peer Reviewed Suggests Ivermectin Key Weapon Against COVID-19 (17-Jun-2021)
- Why Has “Ivermectin” Become a Dirty Word? (18-Jun-2021)
- Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic (18-Jun-2021)
- Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review (21-Jun-2021)
- Comparison Study: Merck Pharma $1.2B from NIH – Molnupiravir v. Ivermectin PDF (21-Jun-2021)
- Covid-19: Cases of delta variant rise by 79%, but rate of growth slows (21-Jun-2021)
- Four Fatal Myocarditis British Airways Pilot (22-Jun-2021)
- Benefits and Risks of Influenza Research: Lessons Learned – Fauci + Collins (22-Jun-2021)
- Ivermectin to be investigated as a possible treatment for COVID-19 (23-Jun-2021)
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis (23-Jun-2021)
- Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination (23-Jun-2021)
- Can Vitamin D Help Protect against COVID? Some studies suggest an impact (24-Jun-2021)
- Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? (24-Jun-2021)
- Deleted coronavirus genome sequences trigger scientific intrigue (24-Jun-2021)
- Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine (25-Jun-2021)
- Cuba’s Covid-19 Vaccine Rivals Pfizer-Biontech/Moderna Efficacy (27-Jun-2021)
- Huge Number of Hospital Workers Still Unvaccinated (28-Jun-2021)
- Response to Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? (28-Jun-2021)
- Leader Rodgers Addresses Forum on the Origins of the COVID-19 Pandemic (29-Jun-2021)
- Ivermectin Molnupiravir Antiviral SARS-CoV2 Treatment Development Timeline (30-Jun-2021)
- Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection (30-Jun-2021)
July 2021
- Ivermectin for Prevention and Treatment of COVID-19 Meta-analysis (July-Aug 2021)
- “What Really Happened In Wuhan?” @TheSeeker268 (1-Jul-2021)
- Analytical Performance of COVID-19 Detection Methods (RT-PCR): Scientific and Societal Concerns (2-Jul-2021)
- Science, not speculation, is essential to determine how SARS-CoV-2 reached humans (5-Jul-2021)
- Fauci-Funded EcoHealth Refuses To Give Wuhan Documents To Congress (5-Jul-2021)
- Evaluation of Messenger RNA in Human Breast Milk (6-Jul-2021)
- FDA Reverses Iself: Rejects Covid Antibody Test Results Insanity Reigns (6-Jul-2021)
- Role of efficient testing and contact tracing in mitigating the COVID-19 pandemic: a network modelling study (7-Jul-2021)
- Do Vaccines Diminish COVID-19 Genomic Diversity? (7-Jul-2021)
- Evaluation of Messenger RNA in Human Breast Milk (7-Jul-2021)
- CDC Post-Vaccine Deaths (7-Jul-2021)
- BBC attempts to discredit Ivermectin studies: Misinformation or Debunking? (8-Jul-2021)
- mRNA Vaccine Myocarditis – Eriksen’s cardiac arrest: “No comment”
- VAERS Meta-Analysis of COVID-19 Vaccine Adverse Fatalities (11-Jul-2021)
- US FDA Warns J&J Vaccine Triggers Severe Guillain- Barré Including Death (12-Jul-2021)
- Human APOBEC3 Variations and Viral Infection (14-Jul-2021)
- Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity (15-Jul-2021)
- UK government hid sick pay scheme for workers isolating with coronavirus (17-Jun-2021)
- Manufacture Covid-19 Vaccines without Pfizer or Moderna? (18-Jul-2021)
- Vaccine Patent Waiver – Vaccine Maker Profits (18-Jul-2021)
- Has Gates Foundation efforts to vaccinate the world against COVID-19 helped — or hindered? (20-Jul-2021)
- Untwisting DNA reveals new force that shapes genomes (22-Jul-2021)
- Eyes wide shut: How newborn mammals dream the world they’re entering (22-Jul-2021)
- Scientists Reverse Age-Related Memory Loss in Mice (22-Jul-2021)
- Exploring the drugability of conserved RNA regulatory elements in the SARS-CoV-2 genome (23-Jul-2021)
- David Frum – Blue Vaccinated Losing Patience With Red Anti-vax (23-Jul-2021)
- 75% of COVID-19 Infections in Singapore are Vaccinated (23-Jul-2021)
- Mask mandates return to the Capitol, White House (28-Jul-2021)
- Pfizer Inc Reports Second Quarter 2021 Results: $19B Growth, 76% Thanks to Vaccine (28-Jul-2021)
- Over and under-estimation of COVID-19 deaths (28-Jul-2021)
- How the coronavirus infects cells — and why Delta is so dangerous (28-Jul-2021)
- IRS Expands Employer Tax Credits for Paid COVID-19 Vaccination Leave (29-Jul-2021)
August 2021
- Pfizer, Moderna Raise Prices Of Covid-19 Coronavirus Vaccines For European Union and Elsewhere (1-Aug-2021)
- Origins of Covid-19 Report – US Foreign Affairs Committee (August 2021)
- Ivermectin Usage in Africa – Report (2-Aug-2019)
- New Report on the Wuhan Lab Details ‘Greatest Coverup of All Time’ (2-Aug-2021)
- One billion doses of Oxford-AstraZeneca COVID-19 vaccine released (4-Aug-2021)
- The association between BMI and metabolically unhealthy status with COVID-19 mortality: Based on 3019 inpatients from Wuhan, China (4-Aug-2021)
- Adumbrations Of Aducanumab (5-Aug-2021)
- NHS/NICE: Vitamin D Supplementation for Covid-19 (5-Aug-2021)
- Surprise—Pfizer Untruthful—Berenson (7-Aug-2021)
- Drugs Shown to Inhibit SARS-CoV-2 in COVID-19 Open Access Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin (10-Aug-2021)
- Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health (11-Aug-2021)
- Lethal Interactions of SARS-CoV-2 with Graphene Oxide: Implications for COVID-19 Treatment (12-Aug-2021)
- CIA’s Extraordinary Role Influencing Liberal Media Outlets Daily Kos, The Daily Beast, Rolling Stone (12-Aug-2021)
- Comparison of Public Health Containment Measures of COVID-19 in China and India (12-Aug-2021)
- Genotoxic stress and viral infection induce transient expression of APOBEC3A and pro-inflammatory genes through two distinct pathways (13-Aug-2021)
- Freedom of Information request on clinical trial data for the Pfizer/BioNTech vaccine in children aged 12-15 (FOI 21-678) (13-Aug-2021)
- Dr Tess Lawrie Interview on Ivermectin Meta Analyses and Politicisation of Pandemics (15-Aug-2021)
- Self-Fulfilling Prophecy: Systemic Collapse and Pandemic Simulation by Fabio Vighi (16-Aug-2021)
- Corporate Justifications: Why would Pfizer and Moderna raise their Covid-19 vaccine prices? What consequences? (16-Aug-2021)
- Fabio Vighi: Systemic Collapse and Pandemic Simulation (16-Aug-2021)
- Inadvertent Intravenous Injection of mRNA Vaccine Myopericarditis – Chamber Asperation Needed (17-Aug-2021)
- Rapid initiation of nasal saline irrigation: hospitalizations in COVID-19 patients randomized to alkalinization or povidone-iodine compared to a national dataset (17-Aug-2021)
- Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? (18-Aug-2021)
- Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis (18-Aug-2021)
- Reuters: Where’s the data on delta? Lack of testing info makes it hard to see virus’s full scope (19-Aug-2021)
- Highly Vaccinated Israel Is Seeing A Dramatic Surge In New COVID Cases. Here’s Why (20-Aug-2021)
- A Review of the Evidence: Studies of Mask Efficacy – Do Masks Work? (22-Aug-2021)
- mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern (23-Aug-2021)
- Natural infection versus vaccination: Differences in COVID antibody responses emerge (24-Aug-2021)
- COVID-19 has spurred investments in air filtration for K-12 schools – but these technologies aren’t an instant fix (24-Aug-2021)
- Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections (25-Aug-2021)
- Delta Air Lines Charges Unvaccinated Workers $200 Monthly Premium Surcharge (26-Aug-2021)
- Jaw-Dropping Academic Study Shows Natural Immunity Superior to COVID Vaccine (26-Aug-2021)
- The FDA’s ‘Bait and Switch’ with Pfizer’s COVID Vaccine (27-Aug-2021)
- Durability of Spike Immunoglobin G Antibodies to SARS-CoV-2 Among Health Care Workers With Prior Infection (30-Aug-2021)
- Staying ‘Covid-safe’: Proposals for embedding behaviours that protect against Covid-19 transmission in the UK (31-Aug-2021)
-
“In vivo evidence that inadvertent intravenous injection of COVID-19 mRNA vaccines may induce myopericarditis. Brief withdrawal of syringe plunger to exclude blood aspiration may be one possible way to reduce such risk. Both Pfizer/BioNTech and Moderna have clearly stated that their vaccines should only be given via IM route. CDC/UK/WHO guidelines do not instruct this necessary technique.”
September 2021
- COVID Paid Sick Leave Is Expiring – Biden Administration and Congressional Dems are Stonewalling (Sept-2021)
- Prior exposure to common cold coronaviruses enhances immune response to SARS-CoV-2 (2-Sept-2021)
- UK government vaccines watchdog rules out Covid jabs for children (3-Sept-2021)
- US Daily State-by-State Testing Trends (3-Sept-2021)
- COVID-19 mRNA vaccination leading to CNS inflammation: a case series (4-Sept-2021)
- Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment (5-Sept-2021)
- More than 900 pages of materials related to US.-funded coronavirus research in China were released following a FOIA lawsuit by The Intercept (6-Sept-2021)
- List of OTC Prophylactics and Treatments for Covid-19 plus Specific Dosages (7-Sept-2021)
- Study shows 80% COVID-19 antibodies lost six months after second Pfizer vaccine dose (8-Sept-2021)
- Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report (8-Sept-2021)
- Vaccine antibodies lost after 6 months: supports CDC recommendation for booster shots especially for the elderly (8-Sept-2021)
- Matt Taibbi: Moral Majority Strikes Again – Maddow, Rolling Stone and Ivermectin: Lies That Cost Lives (8-Sept-2021)
- CDC: Vaccine Safety Tracking Myocarditis November 2019 to July 2021 (8-Sept-2021)
- Two Things Mainstream Media Didn’t Tell You About FDA’s Approval of Pfizer Vaccine
- ‘Appalled’ by Vaccine Booster Plans, WHO Chief Rebukes Big Pharma, Rich Nations (9-Sept-2021)
- Executive Order on Requiring Coronavirus Disease 2019 Vaccination for Federal Employees | The White House (9-Sept-2021)
- SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis (8-Sept-2021)
- Merriam-Webster’s partisanship is showing – again – with its anti-vax definition (9-Sept-2021)
- Combined Impact of Prior SARS-CoV-2 Infection and Vaccination on Antibody Presence (9-Sept-2021)
- KFF: Vaccination Data Based on Race/Ethnicity (9-Sept-2021)
- Thomas Neuburger: Our Two Covid Problems (9-Sept-2021)
- Australian Government Restricts Doctor Prescribing Ivermectin Antivirals (10-Sept-2021)
- Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study (10-Sept-2021)
- Detroit TV Facebook Group: Send Unvaccinated Stories Got 20,000+ Vaccine Horror Stories (10-Sept-2021)
- Vaccinating people who have had covid-19: why doesn’t natural immunity count in the US? (13-Sept-2021)
- The tangled history of mRNA vaccines (14-Sept-2021)
- Big Pharma Secrets Revealed as Group Uncovers Portion of Pfizer Vaccine Recipe (15-Sept-2021)
- New restrictions on prescribing ivermectin for COVID-19 in Australia (15-Sept-2021)
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis (16-Sept-2021)
- Estimates of post-acute symptoms among people with COVID-19 in the UK 26-Apr-2020 to 1-Aug-2021 (16-Sept-2021)
- An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 (17-Sept-2021)
- A comprehensive survey of bat sarbecoviruses across China for the origin tracing of SARS-CoV and SARS-CoV-2 (20-Sept-2021)
- Syndemic Framework Evaluation of Severe COVID-19 Outcomes in the United States: Factors Associated With Race and Ethnicity (20-Sept-2021)
- COVID-19 Outbreaks in Settings With Precarious Housing Conditions in Germany: Challenges and Lessons Learned (21-Sept-2021)
- DEFUSE: Gain-of-Function Wuhan Ecohealth NIH Funding Docs (21-Sept-2021)
- ‘Ultra-potent’ antibody against SARS-CoV-2 variants isolated (22-Sept-2021)
- FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations (22-Sept-2021)
- The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units (22-Sept-2021)
- EU unable to cap COVID-19 vaccine prices in secret deals (23-Sept-2021)
- VIDEO: Inadvertent Intravenous Injection of mRNA Spike Protein via Covid Vaccines (26-Sept-2021)
- Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomised Controlled Trials (28-Sept-2021)
- Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 (28-Sept-2021)
- Harvard Study: Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States (30-Sept-2021)
- Response to the COVID-19 Pandemic: Comparison of Strategies in Six Countries (30-Sept-2021)
- 76% of September Covid-19 deaths are vax breakthroughs (30-Sept-2021)
October 2021
- Covid antiviral pill can halve risk of hospitalisation (1-Oct-2021)
- The NYT’s Partisan Tale about COVID and the Unvaccinated is Rife with Sloppy Data Analysis (1-Oct-2021)
- Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalisation or Death by 50% Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study (1-Oct-2021)
- Post infection natural immunity, debate and implications for mandatory vaccinations (2-Oct-2021)
- Pfizer Scientist: “Your Antibodies are Probably Better than the Vaccination” (4-Oct-2021)
- Lee Camp Exposes Bill Gates and the Hidden Side of His Capitalist Projects (4-Oct-2021)
- Merck Sells Federally Financed Covid Pill to U.S. for 40x What It Costs To Make (5-Oct-2021)
- Unearthed Video From 2019 Reveals Fauci Contradictions on mRNA Vaccines (6-Oct-2021)
- Coronavirus (COVID-19): Press Conference with Michael Mina, 10/06/21 (6-Oct-2021)
- Plans for a “Universal mRNA Flu Vaccine” Which Became the COVID-19 mRNA Vaccine (6-Oct-2021)
- Real-world data show that filters clean COVID-causing virus from air (6-Oct-2021)
- Pfizer Vaccine Efficacy Declines to 47% 6 Months After 2nd Dose (6-Oct-2021)
- CDC Director Overrules Expert Panel on Booster Policy (6-Oct-2021)
- Army to highlight future pandemic preparedness efforts at AUSA (6-Oct-2021)
- Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination (7-Oct-2021)
- A Nudge Too Far? The Rise of Behavioural Science and Technocratic Rule (10-Oct-2021)
- Greg Abbot Prefers People Getting Covid to Freedom of Association (10-Oct-2021)
- Bacteria underlie success of faecal microbiota transplants (10-Oct-2021)
- Aaron Siri: Scientists Sue the FDA for Data it Relied Upon to License Pfizer’s Covid-19 Vaccine (11-Oct-2021)
- Scientists discover a highly potent antibody against SARS-CoV-2 (11-Oct-2021)
- The impact of heating, ventilation, and air conditioning design features on the transmission of viruses, including the 2019 novel coronavirus: a systematic review of ventilation and coronavirus (11-Oct-2021)
- Doctors Without Borders Slams U.S. for Hoarding 500 Million Vaccine Doses (11-Oct-2021)
- Far-right Covid conspiracy theories fuelling antisemitism, warn UK experts (12-Oct-2021)
- Texas Bans COVID-19 Vaccination Mandates (12-Oct-2021)
- The ‘Covid Report’ exposed that behavioural science cost countless lives (14-Oct-2021)
- Matt Taibbi: The Cult of the Vaccine (8-Oct-2021)
- Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 (14-Oct-2021)
- Haiti To Return 250,000 COVID-19 Vaccines To COVAX Facility (15-Oct-2021)
- Counterproductive FactChecking: Merck, Pfizer COVID-19 Antivirals Different From Ivermectin (15-Oct-2021)
- 141 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted (17-Oct-2021)
- The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity (21-Oct-2021)
- In Major Shift, NIH Admits Funding Risky Virus Research in Wuhan (22-Oct-2021)
- Predictors of SARS-CoV-2 infection following high-risk exposure (23-Oct-2021)
- COVID-19 Vaccine Perceptions and Uptake in a National Prospective Cohort of Essential Workers (23-Oct-2021)
- The Mask-Wearing Bias In The Estimates Of Vaccine Efficacy (23-Oct-2021)
- COVID-19 pandemic lockdowns sharply increased bicycle-related injuries; gun-related injuries rose too (24-Oct-2021)
- John Campbell: Decline Vaccine Efficacy? (24-Oct-2021)
- Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off (26-Oct-2021)
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial (27-Oct-2021)
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab (27-Oct-2021)
- Covid-19 Vaccine Manufacturers Can Harm You With Near Complete Impunity (27-Oct-2021)
- COVID-19: Moderna Gets Its Miracle (29-Oct-2021)
- Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 (29-Oct-2021)
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study (29-Oct-2021)
- Watch: MEPs Protest “Oppressive” Vaccine Passports, Question Why “Political Elites Push This Agenda This Hard” (31-Oct-2021)
November 2021
- Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups (Nov-2021)
- Ventavia Research – Paving the way for new medicine (1-Nov-2021)
- Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2 (2-Nov-2021)
- Covid’s casualties: How the pandemic shifted South and hit a younger and whiter population (2-Nov-2021)
- Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial (2-Nov-2021)
- Senator Johnson Expert Panel on Federal Vaccine Mandates and Vaccine Injuries (2-Nov-2021)
- Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain (3-Nov-2021)
- UK: First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA (4-Nov-2021)
- Here’s Why Rapid COVID Tests Are So Expensive and Hard to Find (4-Nov-2021)
- Pfizer Novel Covid-19 Oral Antiviral Treatment Candidate (5-Nov-2021)
- Treatment Candidate Reduced Risk of Hospitalization or Death by 89% (Interim Analysis Phase 2/3 Epic-HR Study) (5-Nov-2021)
- Abstract 10712: mRNA COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning (8-Nov-2021) [?]
- SARS-CoV-2 indoor air transmission is a threat that can be addressed with science (9-Nov-2021)
- Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities (10-Nov-2021)
- Mexico’s World Bank Funded Mandatory Biuometric Database Raises Serious Ethical and Legal Questions (10-Nov-2021)
- A study of the benefits of vaccine mandates and vaccine passports for SARS-CoV-2 (11-Nov-2021)
- Ireland: Sick Bill Leave (11-Nov-2021)
- Twitter: @DavidAdeGrayDC Thread (15-Nov-2021)
- Why are Moderna’s Billionaires Airbrushing Scientists Out of the Vaccine Patent Picture? (15-Nov-2021)
- A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2 (15-Nov-2021)
- Continued Effectiveness of COVID-19 Vaccination among Urban Healthcare Workers during Delta Variant Predominance (16-Nov-2021)
- FDA Asks Federal Judge to Grant it Until the Year 2076 to Fully Release Pfizer’s COVID-19 Vaccine Data (17-Nov-2021)
- Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis (18-Nov-2021)
- Plant-derived antiviral drug is effective in blocking highly infectious SARS-CoV-2 Delta variant (19-Nov-2021)
- Efficacy & Safety of BNT162b2 booster – C4591031 2 month interim analysis (19-Nov-2021)
- Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021 (19-Nov-2021)
- AstraZeneca unveils antibody treatment, preventative shot for those who can’t get vaccinated (19-Nov-2021)
- mRNA COVID-19 Vaccination Increases Endothelial Inflammatory Markers and ACS Risk (22-Nov-2021) [?]
- Cuba’s bet on home-grown COVID vaccines is paying off (22-Nov-2021)
- Some GOP states carving out “natural immunity” exception to COVID vaccine requirements (24-Nov-2021)
- Preventing the next pandemic: Inside the quest to find a universal vaccine against all coronaviruses (24-Nov-2021)
- Reddit: Examining Covid-19 Cases, Hospitalisations & Death Rates in the UK before and after the Vaccine programme roll-out (25-Nov-2021)
- Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern (26-Nov-2021)
- Canada’s Unions Welcome Federal Legislation on Paid Sick Leave and Protecting Health Care Workers (26-Nov-2021)
- With federal COVID-19 sick leave gone, workers feel pressure to go to work (30-Nov-2021)
December 2021
- CBC: Travel Bans – ‘Why Is It Only Africa?’ (2-Dec-2021)
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar (9-Dec-2021)
- Court-Ordered Pfizer Documents They Tried to Have Sealed for 55 Years Show 1223 Deaths, 158,000 Adverse Events in 90 Days Post EUA Release (9-Dec-2021)
- FLCCC Protocols: A Guide to Management of COVID-19 (11-Dec-2021)
- Florida Surgeon General Promotes Nutraceuticals for COVID (13-Dec-2021)
- Green Party Black Caucus: We Say No To Mandates (13-Dec-2021)
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (14-Dec-2021)
- HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung (15-Dec-2021)
- Latest Data on COVID-19 Vaccinations by Race/Ethnicity (15-Dec-2021)
- Evidence for a mouse origin of the SARS-CoV-2 Omicron variant (15-Dec-2021)
- Canadian Covid Care Alliance: Innoculations – More Harm Than Good? (16-Dec-2021)
- Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy (16-Dec-2021)
- South Africa Hospitalization Rate Plunges in Omicron Wave (17-Dec-2021)
- The Atlantic: I Canceled My Birthday Party Because of Omicron (17-Dec-2021)
- NIH Directors Fauci and Collins Target the Great Barrington Declaration (18-Dec-2021)
- The Belly of The Daily Beast and Its Perceptible Ties to the CIA (19-Dec-2021)
- US Army Creates Single Vaccine Against All COVID & SARS Variants, Researchers Say (21-Dec-2021)
- Australia rules out lockdowns despite Omicron surge (21-Dec-2021)
- Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination (21-Dec-2021)
- Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations (21-Dec-2021)
- Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection (22-Dec-2021)
- Scott Morrison flags changes to Australia’s COVID-19 approach after National Cabinet meeting (22-Dec-2021)
- Analysis Of Football Injury Data From 2015-2021. Are Heart-Related Injuries More Frequent In The Year 2021? (26-Dec-2021)
- Video: Fauci Admits Mandates Are ‘Just a Mechanism’ To Get More People Vaccinated (28-Dec-2021)
- Freedom of Information Law Suit against CDC Refusal to Provide Public Data (28-Dec-2021)
- Once a ‘crazy idea,’ patent-pooling nonprofit will help bring COVID-19 pills to world’s poor (29-Dec-2021)
- COVID in Europe: New Year events curbed as Omicron surge brings record infections (31-Dec-2021)
- VIDEO: The First Omicron Death (31-Dec-2021)
HAPPY NEW YEAR 2022!